

**CORYNEBACTERIUM GLUTAMICUM GENES ENCODING PROTEINS  
INVOLVED IN MEMBRANE SYNTHESIS AND MEMBRANE TRANSPORT**

5    **Related Applications**

          This application claims priority to prior filed U.S. Provisional Patent Application  
Serial No. 60/141031, filed June 25, 1999, U.S. Provisional Patent Application Serial  
No. 60/143262, filed July 9, 1999, and U.S. Provisional Patent Application Serial No.  
60/151281, filed August 27, 1999. This application also claims priority to prior filed  
10   German Patent Application No. 19930487.4, filed July 1, 1999, German Patent  
Application No. 19930489.0, filed July 1, 1999, German Patent Application  
No. 19931549.3, filed July 8, 1999, German Patent Application No. 19931550.7, filed  
July 8, 1999, German Patent Application No. 19932134.5, filed July 9, 1999, German  
Patent Application No. 19941379.7, filed August 31, 1999, German Patent Application  
15   No. 19942088.2, filed September 3, 1999, and German Patent Application No.  
19942097.1, filed September 3, 1999. The entire contents of all of the aforementioned  
applications are hereby expressly incorporated herein by this reference.

**Background of the Invention**

20       Certain products and by-products of naturally-occurring metabolic processes in  
cells have utility in a wide array of industries, including the food, feed, cosmetics, and  
pharmaceutical industries. These molecules, collectively termed 'fine chemicals',  
include organic acids, both proteinogenic and non-proteinogenic amino acids,  
nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic  
25   compounds, vitamins and cofactors, and enzymes. Their production is most  
conveniently performed through the large-scale culture of bacteria developed to produce  
and secrete large quantities of one or more desired molecules. One particularly useful  
organism for this purpose is *Corynebacterium glutamicum*, a gram positive,  
nonpathogenic bacterium. Through strain selection, a number of mutant strains have  
30   been developed which produce an array of desirable compounds. However, selection of  
strains improved for the production of a particular molecule is a time-consuming and  
difficult process.

**Summary of the Invention**

35       The invention provides novel bacterial nucleic acid molecules which have a  
variety of uses. These uses include the identification of microorganisms which can be  
used to produce fine chemicals, the modulation of fine chemical production in *C.*

*glutamicum* or related bacteria, the typing or identification of *C. glutamicum* or related bacteria, as reference points for mapping the *C. glutamicum* genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as membrane construction and membrane transport (MCT) proteins.

5           *C. glutamicum* is a gram positive, aerobic bacterium which is commonly used in industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The MCT nucleic acid molecules of the invention, therefore, can be used to identify microorganisms which can be used to produce fine chemicals, *e.g.*, by  
10   fermentation processes. Modulation of the expression of the MCT nucleic acids of the invention, or modification of the sequence of the MCT nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism (*e.g.*, to improve the yield or production of one or more fine chemicals from a *Corynebacterium* or *Brevibacterium* species).

15           The MCT nucleic acids of the invention may also be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof, or to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or  
20   mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present. Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to species pathogenic in humans, such as *Corynebacterium diphtheriae* (the causative agent of diphtheria); the detection of such organisms is of  
25   significant clinical relevance.

          The MCT nucleic acid molecules of the invention may also serve as reference points for mapping of the *C. glutamicum* genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered *Corynebacterium* or *Brevibacterium* species.

30           The MCT proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function involved in the metabolism (*e.g.*, the biosynthesis or degradation) of compounds necessary for membrane biosynthesis, or of assisting in the transmembrane transport of one or more compounds either into or out of the cell. Given the availability of cloning vectors for use in *Corynebacterium*  
35   *glutamicum*, such as those disclosed in Sinskey *et al.*, U.S. Patent No. 4,649,119, and techniques for genetic manipulation of *C. glutamicum* and the related *Brevibacterium* species (*e.g.*, *lactofermentum*) (Yoshihama *et al*, *J. Bacteriol.* 162: 591-597 (1985);

Katsumata *et al.*, *J. Bacteriol.* 159: 306-311 (1984); and Santamaria *et al.*, *J. Gen. Microbiol.* 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals. This improved production or efficiency of  
5 production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.

There are a number of mechanisms by which the alteration of an MCT protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein.  
10 Those MCT proteins involved in the export of fine chemical molecules from the cell may be increased in number or activity such that greater quantities of these compounds are secreted to the extracellular medium, from which they are more readily recovered. Similarly, those MCT proteins involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals (*e.g.*, phosphate, sulfate, nitrogen  
15 compounds, etc.) may be increased in number or activity such that these precursors, cofactors, or intermediate compounds are increased in concentration within the cell. Further, fatty acids and lipids themselves are desirable fine chemicals; by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or  
20 more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from *C. glutamicum*.

The mutagenesis of one or more MCT genes of the invention may also result in MCT proteins having altered activities which indirectly impact the production of one or  
25 more desired fine chemicals from *C. glutamicum*. For example, MCT proteins of the invention involved in the export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the overproduction of the desired fine chemical) are efficiently exported before they are able to damage nucleotides and proteins within the cell (which would decrease  
30 the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the yield, production, or efficiency of production of the desired fine chemical). Further, the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell, so by increasing the activity or number of transporters able to export this compound from the cell, one may increase the viability of  
35 the cell in culture, in turn leading to a greater number of cells in the culture producing the desired fine chemical. The MCT proteins of the invention may also be manipulated such that the relative amounts of different lipid and fatty acid molecules are produced.

This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, as well as the integrity of the cell, both of which have a profound effect on the production of fine chemicals from *C. glutamicum* in large-scale fermentative culture.

The invention provides novel nucleic acid molecules which encode proteins, referred to herein as MCT proteins, which are capable of, for example, participating in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. Nucleic acid molecules encoding an MCT protein are referred to herein as MCT nucleic acid molecules. In a preferred embodiment, the MCT protein participates in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. Examples of such proteins include those encoded by the genes set forth in Table 1.

Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (e.g., cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an MCT protein or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection or amplification of MCT-encoding nucleic acid (e.g., DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in Appendix A or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80% or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth in Appendix A, or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in Appendix B. The preferred MCT proteins of the present invention also preferably possess at least one of the MCT activities described herein.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B, e.g., sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains an MCT activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the

metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of Appendix B (e.g., an entire amino acid sequence selected from those sequences set forth in Appendix B). In another preferred embodiment, the protein is a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).

In another preferred embodiment, the isolated nucleic acid molecule is derived from *C. glutamicum* and encodes a protein (e.g., an MCT fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.

In another embodiment, the isolated nucleic acid molecule is at least 15 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of Appendix A. Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More preferably, the isolated nucleic acid encodes a naturally-occurring *C. glutamicum* MCT protein, or a biologically active portion thereof.

Another aspect of the invention pertains to vectors, e.g., recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which such vectors have been introduced. In one embodiment, such a host cell is used to produce an MCT protein by culturing the host cell in a suitable medium. The MCT protein can be then isolated from the medium or the host cell.

Yet another aspect of the invention pertains to a genetically altered microorganism in which an MCT gene has been introduced or altered. In one embodiment, the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated MCT sequence as a transgene. In another embodiment, an endogenous MCT gene within the genome of the microorganism has been altered, e.g., functionally disrupted, by homologous recombination with an altered MCT gene. In another embodiment, an endogenous or introduced MCT gene in a microorganism has been altered by one or more point

mutations, deletions, or inversions, but still encodes a functional MCT protein. In still another embodiment, one or more of the regulatory regions (*e.g.*, a promoter, repressor, or inducer) of an MCT gene in a microorganism has been altered (*e.g.*, by deletion, truncation, inversion, or point mutation) such that the expression of the MCT gene is modulated. In a preferred embodiment, the microorganism belongs to the genus *Corynebacterium* or *Brevibacterium*, with *Corynebacterium glutamicum* being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.

10 In another aspect, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (*e.g.*, the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject.

15 Still another aspect of the invention pertains to an isolated MCT protein or a portion, *e.g.*, a biologically active portion, thereof. In a preferred embodiment, the isolated MCT protein or portion thereof can participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. In another preferred embodiment, the isolated MCT protein or portion thereof is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes.

20 The invention also provides an isolated preparation of an MCT protein. In preferred embodiments, the MCT protein comprises an amino acid sequence of Appendix B. In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame set forth in Appendix A). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of Appendix B. In other embodiments, the isolated MCT protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1.

Alternatively, the isolated MCT protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%, or 90%, and even more preferably at least about 5 95%, 96%, 97%, 98%, or 99% or more homologous, to a nucleotide sequence of Appendix B. It is also preferred that the preferred forms of MCT proteins also have one or more of the MCT bioactivities described herein.

The MCT polypeptide, or a biologically active portion thereof, can be operatively linked to a non-MCT polypeptide to form a fusion protein. In preferred 10 embodiments, this fusion protein has an activity which differs from that of the MCT protein alone. In other preferred embodiments, this fusion protein participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. In particularly preferred embodiments, integration of this fusion protein into a host cell modulates 15 production of a desired compound from the cell.

In another aspect, the invention provides methods for screening molecules which modulate the activity of an MCT protein, either by interacting with the protein itself or a substrate or binding partner of the MCT protein, or by modulating the transcription or translation of an MCT nucleic acid molecule of the invention.

20 Another aspect of the invention pertains to a method for producing a fine chemical. This method involves the culturing of a cell containing a vector directing the expression of an MCT nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector 25 directing the expression of an MCT nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus *Corynebacterium* or *Brevibacterium*, or is selected from those strains set forth in Table 3.

Another aspect of the invention pertains to methods for modulating production of 30 a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates MCT protein activity or MCT nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more *C. glutamicum* metabolic pathways for cell membrane components or is modulated for the transport of 35 compounds across such membranes, such that the yields or rate of production of a desired fine chemical by this microorganism is improved. The agent which modulates MCT protein activity can be an agent which stimulates MCT protein activity or MCT

nucleic acid expression. Examples of agents which stimulate MCT protein activity or MCT nucleic acid expression include small molecules, active MCT proteins, and nucleic acids encoding MCT proteins that have been introduced into the cell. Examples of agents which inhibit MCT activity or expression include small molecules and antisense  
5 MCT nucleic acid molecules.

Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant MCT gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can  
10 take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino  
15 acid is L-lysine.

### **Detailed Description of the Invention**

The present invention provides MCT nucleic acid and protein molecules which are involved in the metabolism of cellular membrane components in *C. glutamicum* or in the transport of compounds across such membranes. The molecules of the invention  
20 may be utilized in the modulation of production of fine chemicals from microorganisms, such as *C. glutamicum*, either directly (*e.g.*, where overexpression or optimization of a fatty acid biosynthesis protein has a direct impact on the yield, production, and/or efficiency of production of the fatty acid from modified *C. glutamicum*), or may have an  
25 indirect impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound (*e.g.*, where modulation of the metabolism of cell membrane components results in alterations in the yield, production, and/or efficiency of production or the composition of the cell membrane, which in turn may impact the production of one or more fine chemicals). Aspects of the invention are  
30 further explicated below.

#### **I. Fine Chemicals**

The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to,  
35 the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases,



nucleosides, and nucleotides (as described *e.g.* in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (*e.g.*, arachidonic acid), diols (*e.g.*, propane diol, and butane diol), carbohydrates (5 *e.g.*, hyaluronic acid and trehalose), aromatic compounds (*e.g.*, aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and 10 Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine 15 chemicals are further explicated below.

#### A. Amino Acid Metabolism and Uses

Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term "amino acid" is art- 20 recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in proteins (see Ullmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L- 25 amino acids are generally the only type found in naturally-occurring proteins. Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3<sup>rd</sup> edition, pages 578-590 (1988)). The 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, 30 and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino 35 acids must be supplied from the diet in order for normal protein synthesis to occur.

Aside from their function in protein biosynthesis, these amino acids are interesting chemicals in their own right, and many have been found to have various

applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L-methionine are common feed additives. (Leuchtenberger, W. (1996) Amino acids – technical production and use, p. 466-502 in Rehm *et al.* (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH: Weinheim, 1985.

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of  $\alpha$ -ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain  $\beta$ -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase. Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3<sup>rd</sup> ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways, see Stryer, L. Biochemistry, 3<sup>rd</sup> ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

*B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses*

Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such molecules are vitamins, antioxidants, and also certain lipids (e.g., polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999) Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley

& Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).

5           Thiamin (vitamin B<sub>1</sub>) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B<sub>2</sub>) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5'-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of compounds collectively termed 'vitamin B<sub>6</sub>' (e.g., pyridoxine, pyridoxamine, pyridoxa-  
10 5'-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)-β-alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of β-alanine and pantoic acid. The  
15 enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β-alanine and for the condensation to pantothenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5'-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of  
20 pantothenate, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B<sub>5</sub>), pantetheine (and its derivatives) and coenzyme A.

Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in  
25 Fe-cluster synthesis and are members of the nifS class of proteins. Lipoic acid is derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α-ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which in turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-  
30 methylpterin. The biosynthesis of folic acid and its derivatives, starting from the metabolism intermediates guanosine-5'-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.

Corrinoids (such as the cobalamines and particularly vitamin B<sub>12</sub>) and porphyrines belong to a group of chemicals characterized by a tetrapyrrole ring system.  
35 The biosynthesis of vitamin B<sub>12</sub> is sufficiently complex that it has not yet been completely characterized, but many of the enzymes and substrates involved are now known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are

also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.

5 The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B<sub>6</sub>, pantothenate, and biotin. Only Vitamin B<sub>12</sub> is produced solely by fermentation, due to the complexity of its synthesis. *In vitro* methodologies require significant inputs of materials and time, often at great cost.

10

### *C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses*

Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of  
15 nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules which serve as precursors to nucleotides, but which are lacking the phosphoric acid  
20 moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores  
25 (*i.e.*, AMP) or as coenzymes (*i.e.*, FAD and NAD).

Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (*e.g.* Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of *de novo* pyrimidine and purine biosynthesis as chemotherapeutic agents." *Med. Res. Reviews* 10: 505-548). Studies of  
30 enzymes involved in purine and pyrimidine metabolism have been focused on the development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." *Curr. Opin. Struct. Biol.* 5: 752-757; (1995) *Biochem Soc. Transact.* 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates  
35 in the biosynthesis of several fine chemicals (*e.g.*, thiamine, S-adenosyl-methionine, folates, or riboflavin), as energy carriers for the cell (*e.g.*, ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (*e.g.*, IMP or GMP) or for

several medicinal applications (see, for example, Kuninaka, A. (1996) *Nucleotides and Related Compounds in Biotechnology* vol. 6, Rehm *et al.*, eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.

The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) "*de novo* purine nucleotide biosynthesis", in: *Progress in Nucleic Acid Research and Molecular Biology*, vol. 42, Academic Press:, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides", Chapter 8 in: *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'-phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell. Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5'-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.

25

#### *D. Trehalose Metabolism and Uses*

Trehalose consists of two glucose molecules, bound in  $\alpha, \alpha$ -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto *et al.*, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) *Trends Biotech.* 16: 460-467; Paiva, C.L.A. and Panek, A.D. (1996) *Biotech. Ann. Rev.* 2: 293-314; and Shiosaka, M. (1997) *J. Japan* 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.

35

## II. Membrane Biosynthesis and Transmembrane Transport

Cellular membranes serve a variety of functions in a cell. First and foremost, a membrane differentiates the contents of a cell from the surrounding environment, thus giving integrity to the cell. Membranes may also serve as barriers to the influx of hazardous or unwanted compounds, and also to the efflux of desired compounds. Cellular membranes are by nature impervious to the unfacilitated diffusion of hydrophilic compounds such as proteins, water molecules and ions due to their structure: a bilayer of lipid molecules in which the polar head groups face outwards (towards the exterior and interior of the cell, respectively) and the nonpolar tails face inwards at the center of the bilayer, forming a hydrophobic core (for a general review of membrane structure and function, see Gennis, R.B. (1989) Biomembranes, Molecular Structure and Function, Springer: Heidelberg). This barrier enables cells to maintain a relatively higher concentration of desired compounds and a relatively lower concentration of undesired compounds than are contained within the surrounding medium, since the diffusion of these compounds is effectively blocked by the membrane. However, the membrane also presents an effective barrier to the import of desired compounds and the export of waste molecules. To overcome this difficulty, cellular membranes incorporate many kinds of transporter proteins which are able to facilitate the transmembrane transport of different kinds of compounds. There are two general classes of these transport proteins: pores or channels and transporters. The former are integral membrane proteins, sometimes complexes of proteins, which form a regulated hole through the membrane. This regulation, or 'gating' is generally specific to the molecules to be transported by the pore or channel, rendering these transmembrane constructs selectively permeable to a specific class of substrates; for example, a potassium channel is constructed such that only ions having a like charge and size to that of potassium may pass through. Channel and pore proteins tend to have discrete hydrophobic and hydrophilic domains, such that the hydrophobic face of the protein may associate with the interior of the membrane while the hydrophilic face lines the interior of the channel, thus providing a sheltered hydrophilic environment through which the selected hydrophilic molecule may pass. Many such pores/channels are known in the art, including those for potassium, calcium, sodium, and chloride ions.

This pore and channel-mediated system of facilitated diffusion is limited to very small molecules, such as ions, because pores or channels large enough to permit the passage of whole proteins by facilitated diffusion would be unable to prevent the passage of smaller hydrophilic molecules as well. Transport of molecules by this process is sometimes termed 'facilitated diffusion' since the driving force of a concentration gradient is required for the transport to occur. Permeases also permit facilitated

diffusion of larger molecules, such as glucose or other sugars, into the cell when the concentration of these molecules on one side of the membrane is greater than that on the other (also called 'uniport'). In contrast to pores or channels, these integral membrane proteins (often having between 6-14 membrane-spanning  $\alpha$ -helices) do not form open channels through the membrane, but rather bind to the target molecule at the surface of the membrane and then undergo a conformational shift such that the target molecule is released on the opposite side of the membrane.

However, cells frequently require the import or export of molecules against the existing concentration gradient ('active transport'), a situation in which facilitated diffusion cannot occur. There are two general mechanisms used by cells for such membrane transport: symport or antiport, and energy-coupled transport such as that mediated by the ABC transporters. Symport and antiport systems couple the movement of two different molecules across the membrane (via permeases having two separate binding sites for the two different molecules); in symport, both molecules are transported in the same direction, while in antiport, one molecule is imported while the other is exported. This is possible energetically because one of the two molecules moves in accordance with a concentration gradient, and this energetically favorable event is permitted only upon concomitant movement of a desired compound against the prevailing concentration gradient. Single molecules may be transported across the membrane against the concentration gradient in an energy-driven process, such as that utilized by the ABC transporters. In this system, the transport protein located in the membrane has an ATP-binding cassette; upon binding of the target molecule, the ATP is converted to ADP + Pi, and the resulting release of energy is used to drive the movement of the target molecule to the opposite face of the membrane, facilitated by the transporter. For more detailed descriptions of all of these transport systems, see: Bamberg, E. *et al.*, (1993) "Charge transport of ion pumps on lipid bilayer membranes", *Q. Rev. Biophys.* 26: 1-25; Findlay, J.B.C. (1991) "Structure and function in membrane transport systems", *Curr. Opin. Struct. Biol.* 1:804-810; Higgins, C.F. (1992) "ABC transporters from microorganisms to man", *Ann. Rev. Cell Biol.* 8: 67-113; Gennis, R.B. (1989) "Pores, Channels and Transporters", in: *Biomembranes, Molecular Structure and Function*, Springer: Heidelberg, p. 270-322; and Nikaido, H. and Saier, H. (1992) "Transport proteins in bacteria: common themes in their design", *Science* 258: 936-942, and references contained within each of these references.

The synthesis of membranes is a well-characterized process involving a number of components, the most important of which are lipid molecules. Lipid synthesis may be divided into two parts: the synthesis of fatty acids and their attachment to sn-glycerol-3-phosphate, and the addition or modification of a polar head group. Typical



lipids utilized in bacterial membranes include phospholipids, glycolipids, sphingolipids, and phosphoglycerides. Fatty acid synthesis begins with the conversion of acetyl CoA either to malonyl CoA by acetyl CoA carboxylase, or to acetyl-ACP by acetyltransacylase. Following a condensation reaction, these two product molecules  
5 together form acetoacetyl-ACP, which is converted by a series of condensation, reduction and dehydration reactions to yield a saturated fatty acid molecule having a desired chain length. The production of unsaturated fatty acids from such molecules is catalyzed by specific desaturases either aerobically, with the help of molecular oxygen, or anaerobically (for reference on fatty acid synthesis, see F.C. Neidhardt *et al.* (1996)  
10 *E. coli* and *Salmonella*. ASM Press: Washington, D.C., p. 612-636 and references contained therein; Lengeler *et al.* (eds) (1999) *Biology of Prokaryotes*. Thieme: Stuttgart, New York, and references contained therein; and Magnuson, K. *et al.*, (1993) *Microbiological Reviews* 57: 522-542, and references contained therein). The cyclopropane fatty acids (CFA) are synthesized by a specific CFA-synthase using SAM  
15 as a cosubstrate. Branched chain fatty acids are synthesized from branched chain amino acids that are deaminated to yield branched chain 2-oxo-acids (see Lengeler *et al.*, eds. (1999) *Biology of Prokaryotes*. Thieme: Stuttgart, New York, and references contained therein). Another essential step in lipid synthesis is the transfer of fatty acids onto the polar head groups by, for example, glycerol-phosphate-acyltransferases. The  
20 combination of various precursor molecules and biosynthetic enzymes results in the production of different fatty acid molecules, which has a profound effect on the composition of the membrane.

### III. Elements and Methods of the Invention

25 The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as MCT nucleic acid and protein molecules, which control the production of cellular membranes in *C. glutamicum* and govern the movement of molecules across such membranes. In one embodiment, the MCT molecules participate in the metabolism of compounds necessary for the construction of cellular membranes in  
30 *C. glutamicum*, or in the transport of molecules across these membranes. In a preferred embodiment, the activity of the MCT molecules of the present invention to regulate membrane component production and membrane transport has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the MCT molecules of the invention are modulated in activity, such that  
35 the *C. glutamicum* metabolic pathways which the MCT proteins of the invention regulate are modulated in yield, production, and/or efficiency of production and the transport of compounds through the membranes is altered in efficiency, which either

directly or indirectly modulates the yield, production, and/or efficiency of production of a desired fine chemical by *C. glutamicum*.

The language, "MCT protein" or "MCT polypeptide" includes proteins which participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. Examples of MCT proteins include those encoded by the MCT genes set forth in Table 1 and Appendix A. The terms "MCT gene" or "MCT nucleic acid sequence" include nucleic acid sequences encoding an MCT protein, which consist of a coding region and also corresponding untranslated 5' and 3' sequence regions. Examples of MCT genes include those set forth in Table 1. The terms "production" or "productivity" are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (e.g., kg product per hour per liter). The term "efficiency of production" includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term "yield" or "product/carbon yield" is art-recognized and includes the efficiency of the conversion of the carbon source into the product (i.e., fine chemical). This is generally written as, for example, kg product per kg carbon source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms "biosynthesis" or a "biosynthetic pathway" are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms "degradation" or a "degradation pathway" are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language "metabolism" is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (e.g., the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound.

In another embodiment, the MCT molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as *C. glutamicum*. There are a number of mechanisms by which the alteration of an MCT protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. Those MCT proteins involved in the export

of fine chemical molecules from the cell may be increased in number or activity such that greater quantities of these compounds are secreted to the extracellular medium, from which they are more readily recovered. Similarly, those MCT proteins involved in the import of nutrients necessary for the biosynthesis of one or more fine chemicals (e.g., phosphate, sulfate, nitrogen compounds, etc.) may be increased in number or activity such that these precursor, cofactor, or intermediate compounds are increased in concentration within the cell. Further, fatty acids and lipids themselves are desirable fine chemicals; by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from *C. glutamicum*.

The mutagenesis of one or more MCT genes of the invention may also result in MCT proteins having altered activities which indirectly impact the production of one or more desired fine chemicals from *C. glutamicum*. For example, MCT proteins of the invention involved in the export of waste products may be increased in number or activity such that the normal metabolic wastes of the cell (possibly increased in quantity due to the overproduction of the desired fine chemical) are efficiently exported before they are able to damage nucleotides and proteins within the cell (which would decrease the viability of the cell) or to interfere with fine chemical biosynthetic pathways (which would decrease the yield, production, or efficiency of production of the desired fine chemical). Further, the relatively large intracellular quantities of the desired fine chemical may in itself be toxic to the cell, so by increasing the activity or number of transporters able to export this compound from the cell, one may increase the viability of the cell in culture, in turn leading to a greater number of cells in the culture producing the desired fine chemical. The MCT proteins of the invention may also be manipulated such that the relative amounts of different lipid and fatty acid molecules are produced. This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, as well as the integrity of the cell, both of which have a profound effect on the production of fine chemicals from *C. glutamicum* in large-scale fermentative culture.

The isolated nucleic acid sequences of the invention are contained within the genome of a *Corynebacterium glutamicum* strain available through the American Type Culture Collection, given designation ATCC 13032. The nucleotide sequence of the isolated *C. glutamicum* MCT DNAs and the predicted amino acid sequences of the *C.*

*glutamicum* MCT proteins are shown in Appendices A and B, respectively. Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode proteins involved in the metabolism of cellular membrane components or proteins involved in the transport of compounds  
5 across such membranes.

The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of Appendix B. As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the  
10 selected amino acid sequence, *e.g.*, the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid  
15 sequence.

The MCT protein or a biologically active portion or fragment thereof of the invention can participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or have one or more of the activities set forth in Table 1.

20 Various aspects of the invention are described in further detail in the following subsections:

#### *A. Isolated Nucleic Acid Molecules*

One aspect of the invention pertains to isolated nucleic acid molecules that  
25 encode MCT polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of MCT-encoding nucleic acid (*e.g.*, MCT DNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA  
30 generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3' and 5' ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3' end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is  
35 double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank

- the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated MCT nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which
- 5 naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (e.g., a *C. glutamicum* cell). Moreover, an "isolated" nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.
- 10 A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having a nucleotide sequence of Appendix A, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a *C. glutamicum* MCT DNA can be isolated from a *C. glutamicum* library
- 15 using all or portion of one of the sequences of Appendix A as a hybridization probe and standard hybridization techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989*). Moreover, a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide
- 20 primers designed based upon this sequence (*e.g.*, a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence of Appendix A). For example, mRNA can be isolated from normal endothelial cells (*e.g.*, by the guanidinium-thiocyanate extraction procedure of Chirgwin *et al.* (1979)
- 25 *Biochemistry* 18: 5294-5299) and DNA can be prepared using reverse transcriptase (*e.g.*, Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL). Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in Appendix A. A nucleic
- 30 acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to an MCT nucleotide sequence can be prepared by
- 35 standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in Appendix A. The sequences of

Appendix A correspond to the *Corynebacterium glutamicum* MCT DNAs of the invention. This DNA comprises sequences encoding MCT proteins (*i.e.*, the "coding region", indicated in each sequence in Appendix A), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in Appendix A. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the sequences in Appendix A.

For the purposes of this application, it will be understood that each of the sequences set forth in Appendix A has an identifying RXA, RXN, or RXS number having the designation "RXA", "RXN", or "RXS" followed by 5 digits (*i.e.*, RXA00775, RXN02994, or RXS03221). Each of these sequences comprises up to three parts: a 5' upstream region, a coding region, and a downstream region. Each of these three regions is identified by the same RXA, RXN, or RXS designation to eliminate confusion. The recitation "one of the sequences in Appendix A", then, refers to any of the sequences in Appendix A, which may be distinguished by their differing RXA, RXN, or RXS designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is set forth in Appendix B. The sequences of Appendix B are identified by the same RXA, RXN, or RXS designations as Appendix A, such that they can be readily correlated. For example, the amino acid sequences in Appendix B designated RXA00775, RXN02994, and RXS03221 are translations of the coding regions of the nucleotide sequence of nucleic acid molecules RXA00775, RXN02994, and RXS03221, respectively, in Appendix A. Each of the RXA, RXN, and RXS nucleotide and amino acid sequences of the invention has also been assigned a SEQ ID NO, as indicated in Table 1. For example, as set forth in Table 1, the nucleic acid sequence of RXA00774 is SEQ ID NO:7, and the amino acid sequence of RXA00774 is SEQ ID NO:8.

Several of the genes of the invention are "F-designated genes". An F-designated gene includes those genes set forth in Table 1 which have an 'F' in front of the RXA, RXN, or RXS designation. For example, SEQ ID NO:21, designated, as indicated on Table 1, as "F RXA01245", is an F-designated gene, as are SEQ ID NOs: 35, 39, and 43 (designated on Table 1 as "F RXA01164", "F RXA01168", and "F RXA02062", respectively).

In one embodiment, the nucleic acid molecules of the present invention are not intended to include those compiled in Table 2. In the case of the *dapD* gene, a sequence for this gene was published in Wehrmann, A., *et al.* (1998) *J. Bacteriol.* 180(12): 3159-3165. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version

relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

5 In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences shown in Appendix A, or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences shown in Appendix A is one which is sufficiently complementary to one of the nucleotide sequences shown in Appendix A such that it can hybridize to one of the nucleotide sequences shown in Appendix A, thereby forming a stable duplex.

10 In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%,  
15 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence shown in Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (e.g., 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a  
20 combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, e.g., hybridizes under stringent conditions, to one of the nucleotide sequences shown in Appendix A, or a portion thereof.

25 Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of one of the sequences in Appendix A, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an MCT protein. The nucleotide sequences determined from the cloning of the MCT genes from *C. glutamicum* allows for the generation of probes and  
30 primers designed for use in identifying and/or cloning MCT homologues in other cell types and organisms, as well as MCT homologues from other *Corynebacteria* or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably  
35 about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the sequences set forth in Appendix A, an anti-sense sequence of one of the sequences set forth in Appendix A, or naturally occurring mutants thereof. Primers based on a nucleotide

sequence of Appendix A can be used in PCR reactions to clone MCT homologues. Probes based on the MCT nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an MCT protein, such as by measuring a level of an MCT-encoding nucleic acid in a sample of cells, *e.g.*, detecting MCT mRNA levels or determining whether a genomic MCT gene has been mutated or deleted.

10 In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or equivalent (*e.g.*, an amino acid residue which has a similar side chain as an amino acid residue in one of the sequences of Appendix B) amino acid residues to an amino acid sequence of Appendix B such that the protein or portion thereof is able to participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. Protein members of such membrane component metabolic pathways or membrane transport systems, as described herein, may play a role in the production and secretion of one or more fine chemicals. Examples of such activities are also described herein. Thus, "the function of an MCT protein" contributes either directly or indirectly to the yield, production, and/or efficiency of production of one or more fine chemicals. Examples of MCT protein activities are set forth in Table 1.

30 In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B.

Portions of proteins encoded by the MCT nucleic acid molecules of the invention are preferably biologically active portions of one of the MCT proteins. As used herein, the term "biologically active portion of an MCT protein" is intended to include a portion, *e.g.*, a domain/motif, of an MCT protein that participates in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in



the transport of molecules across these membranes, or has an activity as set forth in Table 1. To determine whether an MCT protein or a biologically active portion thereof can participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these  
5 membranes, an assay of enzymatic activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification.

Additional nucleic acid fragments encoding biologically active portions of an MCT protein can be prepared by isolating a portion of one of the sequences in Appendix  
10 B, expressing the encoded portion of the MCT protein or peptide (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the MCT protein or peptide.

The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown in Appendix A (and portions thereof) due to degeneracy  
15 of the genetic code and thus encode the same MCT protein as that encoded by the nucleotide sequences shown in Appendix A. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in Appendix B. In a still further embodiment, the nucleic acid molecule of the invention encodes a full length *C. glutamicum* protein which is  
20 substantially homologous to an amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).

It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to  
25 the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (*e.g.*, a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at  
30 least 50% identical to the nucleotide sequence designated RXA00777 (SEQ ID NO:5), a nucleotide sequence which is greater than and/or at least 40% identical to the nucleotide sequence designated RXA02439 (SEQ ID NO:17), and a nucleotide sequence which is greater than and/or at least 39% identical to the nucleotide sequence designated RXA00002 (SEQ ID NO:23). One of ordinary skill in the art would be able to calculate  
35 the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated

percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (e.g., at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention.

In addition to the *C. glutamicum* MCT nucleotide sequences shown in Appendix A, it will be appreciated by one of ordinary skill in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of MCT proteins may exist within a population (e.g., the *C. glutamicum* population). Such genetic polymorphism in the MCT gene may exist among individuals within a population due to natural variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding an MCT protein, preferably a *C. glutamicum* MCT protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the MCT gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in MCT that are the result of natural variation and that do not alter the functional activity of MCT proteins are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural variants and non-*C. glutamicum* homologues of the *C. glutamicum* MCT DNA of the invention can be isolated based on their homology to the *C. glutamicum* MCT nucleic acid disclosed herein using the *C. glutamicum* DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of Appendix A. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent

hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of Appendix A corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein). In one embodiment, the nucleic acid encodes a natural *C. glutamicum* MCT protein.

In addition to naturally-occurring variants of the MCT sequence that may exist in the population, one of ordinary skill in the art will further appreciate that changes can be introduced by mutation into a nucleotide sequence of Appendix A, thereby leading to changes in the amino acid sequence of the encoded MCT protein, without altering the functional ability of the MCT protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a sequence of Appendix A. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the MCT proteins (Appendix B) without altering the activity of said MCT protein, whereas an "essential" amino acid residue is required for MCT protein activity. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved in the domain having MCT activity) may not be essential for activity and thus are likely to be amenable to alteration without altering MCT activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding MCT proteins that contain changes in amino acid residues that are not essential for MCT activity. Such MCT proteins differ in amino acid sequence from a sequence contained in Appendix B yet retain at least one of the MCT activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 50% homologous to an amino acid sequence of Appendix B and is capable of participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or has one or more activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to one of the sequences in Appendix B, more preferably at least about 60-70% homologous to one of the sequences in Appendix B, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of the sequences in Appendix B, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the sequences in Appendix B.

To determine the percent homology of two amino acid sequences (*e.g.*, one of the sequences of Appendix B and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence (*e.g.*, one of the sequences of Appendix B) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (*e.g.*, a mutant form of the sequence selected from Appendix B), then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % homology = # of identical positions/total # of positions x 100).

An isolated nucleic acid molecule encoding an MCT protein homologous to a protein sequence of Appendix B can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of Appendix A such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the sequences of Appendix A by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an MCT protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an MCT coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an MCT activity described herein to identify mutants that retain MCT activity. Following mutagenesis of one of the sequences of Appendix A, the encoded protein can be expressed recombinantly and the activity of the

protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification).

In addition to the nucleic acid molecules encoding MCT proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire MCT coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an MCT protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the entire coding region of NO. 3 (RXA00777) comprises nucleotides 1 to 1065). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding MCT. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding MCT disclosed herein (*e.g.*, the sequences set forth in Appendix A), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of MCT mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of MCT mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of MCT mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-

carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a cell or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an MCT protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an  $\alpha$ -anomeric nucleic acid molecule. An  $\alpha$ -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are

capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave MCT mRNA transcripts to thereby inhibit translation of MCT mRNA. A ribozyme having specificity for an MCT-encoding nucleic acid can be designed based upon the nucleotide sequence of an MCT DNA disclosed herein (*i.e.*, NO. 3 (RXA00777 in Appendix A)). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an MCT-encoding mRNA.

See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071 and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, MCT mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, MCT gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an MCT nucleotide sequence (*e.g.*, an MCT promoter and/or enhancers) to form triple helical structures that prevent transcription of an MCT gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

#### B. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an MCT protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector.

However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

5 The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of  
10 interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185,  
15 Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as *cos*-, *tac*-, *trp*-, *tet*-, *trp-tet*-, *lpp*-, *lac*-, *lpp-lac*-, *lacI<sup>q</sup>*-, *T7*-, *T5*-, *T3*-, *gal*-, *trc*-, *ara*-, *SP6*-, *arny*, *SPO2*,  $\lambda$ -*P<sub>R</sub>*- or  $\lambda$  *P<sub>L</sub>*, which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as *ADC1*, *MF $\alpha$* , *AC*, *P-60*, *CYC1*, *GAPDH*, *TEF*, *rp28*, *ADH*, promoters from plants such as *CaMV/35S*, *SSU*, *OCS*, *lib4*, *usp*, *STLS1*, *B33*, *nos* or *ubiquitin*- or *phaseolin*-promoters. It is also possible to use  
20 artificial promoters. It will be appreciated by one of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described  
25 herein (*e.g.*, MCT proteins, mutant forms of MCT proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of MCT proteins in prokaryotic or eukaryotic cells. For example, MCT genes can be expressed in bacterial cells such as *C. glutamicum*, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. *et al.*  
35 (1992) "Foreign gene expression in yeast: a review", *Yeast* 8: 423-488; van den Hondel, C.A.M.J.J. *et al.* (1991) "Heterologous gene expression in filamentous fungi" in: More Gene Manipulations in Fungi, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic

005290-42000000



Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J.F. *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency *Agrobacterium tumefaciens* -mediated transformation of *Arabidopsis thaliana* leaf and cotyledon explants" *Plant Cell Rep.*: 583-586), or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the MCT protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant MCT protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-B1,  $\lambda$ gt11, pBdCl, and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89 ; and

Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident  $\lambda$  prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJ101, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming Streptomyces, while plasmids pUB110, pC194, or pBD214 are suited for transformation of Bacillus species. Several plasmids of use in the transfer of genetic information into Corynebacterium include pHM1519, pBL1, pSA77, or pAJ667 (Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York IBSN 0 444 904018).

One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as *C. glutamicum* (Wada *et al.* (1992) *Nucleic Acids Res.* 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the MCT protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), 2  $\mu$ , pAG-1, Yep6, Yep13, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York (IBSN 0 444 904018).

Alternatively, the MCT proteins of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith *et al.*

(1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In another embodiment, the MCT proteins of the invention may be expressed in unicellular plant cells (such as algae) or in plant cells from higher plants (*e.g.*, the  
5 spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border", *Plant Mol. Biol.* 20: 1195-1197; and Bevan, M.W. (1984) "Binary *Agrobacterium* vectors for plant transformation", *Nucl. Acid. Res.* 12: 8711-8721, and include pLGV23, pGHIac+,  
10 pBIN19, pAK2004, and pDH51 (Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature* 329:840) and pMT2PC  
15 (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook, J., Fritsh, E. F.,  
20 and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type  
25 (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and  
30 Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddell (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Patent No. 4,873,316 and  
35 European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990)

*Science* 249:374-379) and the  $\alpha$ -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to MCT mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, an MCT protein can be expressed in bacterial cells such as *C. glutamicum*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to one of ordinary skill in the art. Microorganisms related to *Corynebacterium glutamicum* which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection", "conjugation" and "transduction" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., linear DNA or RNA (e.g., a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (e.g., a plasmid, phage, phasmid, phagemid,

transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-mediated transfer, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an MCT protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an MCT gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the MCT gene. Preferably, this MCT gene is a *Corynebacterium glutamicum* MCT gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous MCT gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous MCT gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous MCT protein). In the homologous recombination vector, the altered portion of the MCT gene is flanked at its 5' and 3' ends by additional nucleic acid of the MCT gene to allow for homologous recombination to occur between the exogenous MCT gene carried by the vector and an endogenous MCT gene in a microorganism. The additional flanking MCT nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector (see *e.g.*, Thomas, K.R., and Capecchi, M.R. (1987) *Cell* 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (*e.g.*, by electroporation) and

cells in which the introduced MCT gene has homologously recombined with the endogenous MCT gene are selected, using art-known techniques.

In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene.

- 5 For example, inclusion of an MCT gene on a vector placing it under control of the lac operon permits expression of the MCT gene only in the presence of IPTG. Such regulatory systems are well known in the art.

- In another embodiment, an endogenous MCT gene in a host cell is disrupted (e.g., by homologous recombination or other genetic means known in the art) such that  
10 expression of its protein product does not occur. In another embodiment, an endogenous or introduced MCT gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional MCT protein. In still another embodiment, one or more of the regulatory regions (e.g., a promoter, repressor, or inducer) of an MCT gene in a microorganism has been altered (e.g., by deletion,  
15 truncation, inversion, or point mutation) such that the expression of the MCT gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described MCT gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.

- 20 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) an MCT protein. Accordingly, the invention further provides methods for producing MCT proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding an MCT protein has  
25 been introduced, or into which genome has been introduced a gene encoding a wild-type or altered MCT protein) in a suitable medium until MCT protein is produced. In another embodiment, the method further comprises isolating MCT proteins from the medium or the host cell.

30 *C. Isolated MCT Proteins*

- Another aspect of the invention pertains to isolated MCT proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when  
35 chemically synthesized. The language "substantially free of cellular material" includes preparations of MCT protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the

language "substantially free of cellular material" includes preparations of MCT protein having less than about 30% (by dry weight) of non-MCT protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-MCT protein, still more preferably less than about 10% of non-MCT protein, and most preferably less than about 5% non-MCT protein. When the MCT protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of MCT protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of MCT protein having less than about 30% (by dry weight) of chemical precursors or non-MCT chemicals, more preferably less than about 20% chemical precursors or non-MCT chemicals, still more preferably less than about 10% chemical precursors or non-MCT chemicals, and most preferably less than about 5% chemical precursors or non-MCT chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the MCT protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a *C. glutamicum* MCT protein in a microorganism such as *C. glutamicum*.

An isolated MCT protein or a portion thereof of the invention can participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or has one or more of the activities set forth in Table 1. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability participate in the metabolism of compounds necessary for the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, an MCT protein of the invention has an amino acid sequence shown in Appendix B. In yet another preferred embodiment, the MCT protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, to a nucleotide sequence of Appendix A. In still another preferred embodiment, the MCT protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably

at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more

- 5 homologous to one of the nucleic acid sequences of Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited values, (*e.g.*, 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The
- 10 preferred MCT proteins of the present invention also preferably possess at least one of the MCT activities described herein. For example, a preferred MCT protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, to a nucleotide sequence of Appendix A, and which can participate in the metabolism of compounds necessary for
- 15 the construction of cellular membranes in *C. glutamicum*, or in the transport of molecules across these membranes, or which has one or more of the activities set forth in Table 1.

- In other embodiments, the MCT protein is substantially homologous to an amino acid sequence of Appendix B and retains the functional activity of the protein of one of
- 20 the sequences of Appendix B yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the MCT protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or
- 25 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B and which has at least one of the MCT activities described herein. Ranges and identity values intermediate to the
- 30 above-recited values, (*e.g.*, 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence
- 35 of Appendix B.

Biologically active portions of an MCT protein include peptides comprising amino acid sequences derived from the amino acid sequence of an MCT protein, *e.g.*,



the an amino acid sequence shown in Appendix B or the amino acid sequence of a protein homologous to an MCT protein, which include fewer amino acids than a full length MCT protein or the full length protein which is homologous to an MCT protein, and exhibit at least one activity of an MCT protein. Typically, biologically active portions (peptides, *e.g.*, peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of an MCT protein. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of an MCT protein include one or more selected domains/motifs or portions thereof having biological activity.

MCT proteins are preferably produced by recombinant DNA techniques. For example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the MCT protein is expressed in the host cell. The MCT protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, an MCT protein, polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native MCT protein can be isolated from cells (*e.g.*, endothelial cells), for example using an anti-MCT antibody, which can be produced by standard techniques utilizing an MCT protein or fragment thereof of this invention.

The invention also provides MCT chimeric or fusion proteins. As used herein, an MCT "chimeric protein" or "fusion protein" comprises an MCT polypeptide operatively linked to a non-MCT polypeptide. An "MCT polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an MCT protein, whereas a "non-MCT polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the MCT protein, *e.g.*, a protein which is different from the MCT protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to indicate that the MCT polypeptide and the non-MCT polypeptide are fused in-frame to each other. The non-MCT polypeptide can be fused to the N-terminus or C-terminus of the MCT polypeptide. For example, in one embodiment the fusion protein is a GST-MCT fusion protein in which the MCT sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant MCT proteins. In another embodiment, the fusion protein is an MCT protein containing a heterologous signal sequence at its N-terminus. In certain host cells

(e.g., mammalian host cells), expression and/or secretion of an MCT protein can be increased through use of a heterologous signal sequence.

Preferably, an MCT chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An MCT-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the MCT protein.

Homologues of the MCT protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the MCT protein. As used herein, the term "homologue" refers to a variant form of the MCT protein which acts as an agonist or antagonist of the activity of the MCT protein. An agonist of the MCT protein can retain substantially the same, or a subset, of the biological activities of the MCT protein. An antagonist of the MCT protein can inhibit one or more of the activities of the naturally occurring form of the MCT protein, by, for example, competitively binding to a downstream or upstream member of the cell membrane component metabolic cascade which includes the MCT protein, or by binding to an MCT protein which mediates transport of compounds across such membranes, thereby preventing translocation from taking place.

In an alternative embodiment, homologues of the MCT protein can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the MCT protein for MCT protein agonist or antagonist activity. In one embodiment, a variegated library of MCT variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of MCT variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential MCT sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of MCT sequences therein.

There are a variety of methods which can be used to produce libraries of potential MCT homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential MCT sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477.

10 In addition, libraries of fragments of the MCT protein coding can be used to generate a variegated population of MCT fragments for screening and subsequent selection of homologues of an MCT protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an MCT coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the MCT protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of MCT homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify MCT homologues (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

35 In another embodiment, cell based assays can be exploited to analyze a variegated MCT library, using methods well known in the art.

*D. Uses and Methods of the Invention*

The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of *C. glutamicum* and related organisms; mapping of  
5 genomes of organisms related to *C. glutamicum*; identification and localization of *C. glutamicum* sequences of interest; evolutionary studies; determination of MCT protein regions required for function; modulation of an MCT protein activity; modulation of the metabolism of one or more cell membrane components; modulation of the  
10 transmembrane transport of one or more compounds; and modulation of cellular production of a desired compound, such as a fine chemical.

The MCT nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof. Also, they may be used to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides  
15 the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present.

Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to  
20 pathogenic species, such as *Corynebacterium diphtheriae*. *Corynebacterium diphtheriae* is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to distal susceptible tissues of the  
25 body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria  
30 in the latter two regions has resulted in at least 5,000 deaths since 1990.

In one embodiment, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (e.g., the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the  
35 presence or activity of *Corynebacterium diphtheriae* in the subject. *C. glutamicum* and *C. diphtheriae* are related bacteria, and many of the nucleic acid and protein molecules

in *C. glutamicum* are homologous to *C. diphtheriae* nucleic acid and protein molecules, and can therefore be used to detect *C. diphtheriae* in a subject.

5 The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of the genome, but also for functional studies of *C. glutamicum* proteins. For example, to identify the region of the genome to which a particular *C. glutamicum* DNA-binding protein binds, the *C. glutamicum* genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable  
10 labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of *C. glutamicum*, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that  
15 these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as *Brevibacterium lactofermentum*.

The MCT nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The metabolic and transport processes in which the molecules of the invention participate are utilized by a wide variety of  
20 prokaryotic and eukaryotic cells; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein  
25 which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.

Manipulation of the MCT nucleic acid molecules of the invention may result in the production of MCT proteins having functional differences from the wild-type MCT  
30 proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.

The invention provides methods for screening molecules which modulate the activity of an MCT protein, either by interacting with the protein itself or a substrate or binding partner of the MCT protein, or by modulating the transcription or translation of  
35 an MCT nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more MCT proteins of the invention is contacted with one or more test

compounds, and the effect of each test compound on the activity or level of expression of the MCT protein is assessed.

There are a number of mechanisms by which the alteration of an MCT protein of the invention may directly affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. Recovery of fine chemical compounds from large-scale cultures of *C. glutamicum* is significantly improved if *C. glutamicum* secretes the desired compounds, since such compounds may be readily purified from the culture medium (as opposed to extracted from the mass of *C. glutamicum* cells). By either increasing the number or the activity of transporter molecules which export fine chemicals from the cell, it may be possible to increase the amount of the produced fine chemical which is present in the extracellular medium, thus permitting greater ease of harvesting and purification. Conversely, in order to efficiently overproduce one or more fine chemicals, increased amounts of the cofactors, precursor molecules, and intermediate compounds for the appropriate biosynthetic pathways are required. Therefore, by increasing the number and/or activity of transporter proteins involved in the import of nutrients, such as carbon sources (*i.e.*, sugars), nitrogen sources (*i.e.*, amino acids, ammonium salts), phosphate, and sulfur, it may be possible to improve the production of a fine chemical, due to the removal of any nutrient supply limitations on the biosynthetic process. Further, fatty acids and lipids are themselves desirable fine chemicals, so by optimizing the activity or increasing the number of one or more MCT proteins of the invention which participate in the biosynthesis of these compounds, or by impairing the activity of one or more MCT proteins which are involved in the degradation of these compounds, it may be possible to increase the yield, production, and/or efficiency of production of fatty acid and lipid molecules from *C. glutamicum*.

The engineering of one or more MCT genes of the invention may also result in MCT proteins having altered activities which indirectly impact the production of one or more desired fine chemicals from *C. glutamicum*. For example, the normal biochemical processes of metabolism result in the production of a variety of waste products (*e.g.*, hydrogen peroxide and other reactive oxygen species) which may actively interfere with these same metabolic processes (for example, peroxynitrite is known to nitrate tyrosine side chains, thereby inactivating some enzymes having tyrosine in the active site (Groves, J.T. (1999) *Curr. Opin. Chem. Biol.* 3(2): 226-235). While these waste products are typically excreted, the *C. glutamicum* strains utilized for large-scale fermentative production are optimized for the overproduction of one or more fine chemicals, and thus may produce more waste products than is typical for a wild-type *C. glutamicum*. By optimizing the activity of one or more MCT proteins of the invention

which are involved in the export of waste molecules, it may be possible to improve the viability of the cell and to maintain efficient metabolic activity. Also, the presence of high intracellular levels of the desired fine chemical may actually be toxic to the cell, so by increasing the ability of the cell to secrete these compounds, one may improve the viability of the cell.

Further, the MCT proteins of the invention may be manipulated such that the relative amounts of various lipid and fatty acid molecules produced are altered. This may have a profound effect on the lipid composition of the membrane of the cell. Since each type of lipid has different physical properties, an alteration in the lipid composition of a membrane may significantly alter membrane fluidity. Changes in membrane fluidity can impact the transport of molecules across the membrane, which, as previously explicated, may modify the export of waste products or the produced fine chemical or the import of necessary nutrients. Such membrane fluidity changes may also profoundly affect the integrity of the cell; cells with relatively weaker membranes are more vulnerable in the large-scale fermentor environment to mechanical stresses which may damage or kill the cell. By manipulating MCT proteins involved in the production of fatty acids and lipids for membrane construction such that the resulting membrane has a membrane composition more amenable to the environmental conditions extant in the cultures utilized to produce fine chemicals, a greater proportion of the *C. glutamicum* cells should survive and multiply. Greater numbers of *C. glutamicum* cells in a culture should translate into greater yields, production, or efficiency of production of the fine chemical from the culture.

The aforementioned mutagenesis strategies for MCT proteins to result in increased yields of a fine chemical from *C. glutamicum* are not meant to be limiting; variations on these strategies will be readily apparent to one of ordinary skill in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic acid and protein molecules of the invention may be utilized to generate *C. glutamicum* or related strains of bacteria expressing mutated MCT nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any natural product of *C. glutamicum*, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally occur in the metabolism of *C. glutamicum*, but which are produced by a *C. glutamicum* strain of the invention.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, Appendices, and the sequence listing cited throughout this application are hereby incorporated by reference.

5

### Exemplification

#### **Example 1: Preparation of total genomic DNA of *Corynebacterium glutamicum* ATCC 13032**

10 A culture of *Corynebacterium glutamicum* (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose,  
15 2.46 g/l  $\text{MgSO}_4 \times 7\text{H}_2\text{O}$ , 10 ml/l  $\text{KH}_2\text{PO}_4$  solution (100 g/l, adjusted to pH 6.7 with KOH), 50 ml/l M12 concentrate (10 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 1 g/l NaCl, 2 g/l  $\text{MgSO}_4 \times 7\text{H}_2\text{O}$ , 0.2 g/l  $\text{CaCl}_2$ , 0.5 g/l yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l  $\text{FeSO}_4 \times \text{H}_2\text{O}$ , 10 mg/l  $\text{ZnSO}_4 \times 7 \text{H}_2\text{O}$ , 3 mg/l  $\text{MnCl}_2 \times 4 \text{H}_2\text{O}$ , 30 mg/l  $\text{H}_3\text{BO}_3$ , 20 mg/l  $\text{CoCl}_2 \times 6 \text{H}_2\text{O}$ , 1 mg/l  $\text{NiCl}_2 \times 6 \text{H}_2\text{O}$ , 3 mg/l  $\text{Na}_2\text{MoO}_4 \times 2 \text{H}_2\text{O}$ , 500 mg/l complexing agent  
20 (EDTA or critic acid), 100 ml/l vitamins-mix (0.2 mg/l biotin, 0.2 mg/l folic acid, 20 mg/l p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l ca-panthothenate, 140 mg/l nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting  
25 protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 µg/ml, the suspension is incubated for ca.18 h at 37°C. The DNA was purified by  
30 extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20  
35 µg/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30



min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.

5

**Example 2: Construction of genomic libraries in *Escherichia coli* of *Corynebacterium glutamicum* ATCC13032.**

Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (*see e.g.*, Sambrook, J. *et al.* 10 (1989) "Molecular Cloning : A Laboratory Manual", Cold Spring Harbor Laboratory Press, or Ausubel, F.M. *et al.* (1994) "Current Protocols in Molecular Biology", John Wiley & Sons.)

Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) *Proc. Natl. Acad. Sci. USA*, 75:3737-3741); pACYC177 (Change & 15 Cohen (1978) *J. Bacteriol* 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCos1 (Stratagene, LaJolla, USA) or Lorist6 (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) *Gene* 53:283-286. Gene libraries specifically for use in *C. glutamicum* may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

20

**Example 3: DNA Sequencing and Computational Functional Analysis**

Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (*see e.g.*, Fleischman, R.D. *et al.* (1995) "Whole-genome 25 Random Sequencing and Assembly of Haemophilus Influenzae Rd., *Science*, 269:496-512). Sequencing primers with the following nucleotide sequences were used: 5'-GGAAACAGTATGACCATG-3' or 5'-GTAAAACGACGGCCAGT-3'.

**Example 4: *In vivo* Mutagenesis**

30 *In vivo* mutagenesis of *Corynebacterium glutamicum* can be performed by passage of plasmid (or other vector) DNA through *E. coli* or other microorganisms (*e.g.* *Bacillus* spp. or yeasts such as *Saccharomyces cerevisiae*) which are impaired in their capabilities to maintain the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (*e.g.*, mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D. 35 (1996) DNA repair mechanisms, in: *Escherichia coli* and *Salmonella*, p. 2277-2294, ASM: Washington.) Such strains are well known to those of ordinary skill in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) *Strategies* 7: 32-34.

**Example 5: DNA Transfer Between *Escherichia coli* and *Corynebacterium glutamicum***

- Several *Corynebacterium* and *Brevibacterium* species contain endogenous
- 5 plasmids (as e.g., pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J.F. *et al.* (1987) *Biotechnology*, 5:137-146). Shuttle vectors for *Escherichia coli* and *Corynebacterium glutamicum* can be readily constructed by using standard vectors for *E. coli* (Sambrook, J. *et al.* (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. *et al.* (1994) "Current Protocols in
- 10 Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from *Corynebacterium glutamicum* is added. Such origins of replication are preferably taken from endogenous plasmids isolated from *Corynebacterium* and *Brevibacterium* species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903
- 15 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both *E. coli* and *C. glutamicum*, and which can be used for several purposes, including gene over-expression (for reference, see e.g., Yoshihama, M. *et al.* (1985) *J. Bacteriol.* 162:591-597,
- 20 Martin J.F. *et al.* (1987) *Biotechnology*, 5:137-146 and Eikmanns, B.J. *et al.* (1991) *Gene*, 102:93-98).

- Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of *Corynebacterium glutamicum*. Transformation of *C. glutamicum* can be achieved by
- 25 protoplast transformation (Kastsumata, R. *et al.* (1984) *J. Bacteriol.* 159:306-311), electroporation (Liebl, E. *et al.* (1989) *FEMS Microbiol. Letters*, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schäfer, A *et al.* (1990) *J. Bacteriol.* 172:1663-1666). It is also possible to transfer the shuttle vectors for *C. glutamicum* to *E. coli* by preparing plasmid DNA from *C. glutamicum*
- 30 (using standard methods well-known in the art) and transforming it into *E. coli*. This transformation step can be performed using standard methods, but it is advantageous to use an *Mcr*-deficient *E. coli* strain, such as NM522 (Gough & Murray (1983) *J. Mol. Biol.* 166:1-19).

- Genes may be overexpressed in *C. glutamicum* strains using plasmids which
- 35 comprise pCG1 (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, C.M. (1980) *Proc. Natl. Acad. Sci. USA* 77(12): 7176-7180). In addition, genes may be

overexpressed in *C. glutamicum* strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in *C. glutamicum* or other  
5 *Corynebacterium* or *Brevibacterium* species may be accomplished by well-known methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, *e.g.*, DE Patent 19823834), or through the use of transposons. It is also possible to modulate the activity of a gene of interest by  
10 modifying the regulatory regions (*e.g.*, a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional  
15 terminators may also be inserted 3' to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E.L. (1987) *From Genes to Clones – Introduction to Gene Technology*. VCH: Weinheim.

#### **Example 6: Assessment of the Expression of the Mutant Protein**

Observations of the activity of a mutated protein in a transformed host cell rely on  
20 the fact that the mutant protein is expressed in a similar fashion and in a similar quantity to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene product) is to perform a Northern blot (for reference see, for example, Ausubel *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York), in which a primer  
25 designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the  
30 mutant gene. Total cellular RNA can be prepared from *Corynebacterium glutamicum* by several methods, all well-known in the art, such as that described in Bormann, E.R. *et al.* (1992) *Mol. Microbiol.* 6: 317-326.

To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel  
35 *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York). In this process, total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which

specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.

5

**Example 7: Growth of Genetically Modified *Corynebacterium glutamicum* — Media and Culture Conditions**

Genetically modified *Corynebacteria* are cultured in synthetic or natural growth media. A number of different growth media for *Corynebacteria* are both well-known and readily available (Lieb *et al.* (1989) *Appl. Microbiol. Biotechnol.*, 32:205-210; von der Osten *et al.* (1998) *Biotechnology Letters*, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus *Corynebacterium*, in: The Prokaryotes, Volume II, Balows, A. *et al.*, eds. Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or ammonia salts, such as  $\text{NH}_4\text{Cl}$  or  $(\text{NH}_4)_2\text{SO}_4$ ,  $\text{NH}_4\text{OH}$ , nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.

Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt, molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol. Physiology, A

Practical Approach (eds. P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.

5 All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.

Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can  
10 be altered during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or  
15 NH<sub>4</sub>OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the microorganisms, the pH can also be controlled using gaseous ammonia.

The incubation time is usually in a range from several hours to several days. This  
20 time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes. For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably  
25 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 – 300 rpm. Evaporation losses can be diminished by the maintenance of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.

30 If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD<sub>600</sub> of 0.5 – 1.5 using cells grown on agar plates, such as CM plates (10 g/l glucose, 2.5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract,  
35 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the media is accomplished by either introduction of a saline suspension of *C. glutamicum* cells from CM plates or addition of a liquid preculture of this bacterium.

**Example 8 – *In vitro* Analysis of the Function of Mutant Proteins**

- The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) *Enzymes*. Longmans: London; Fersht, (1985) *Enzyme Structure and Mechanism*. Freeman: New York; Walsh, (1979) *Enzymatic Reaction Mechanisms*. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) *Fundamentals of Enzymology*. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) *The Enzymes*, 3<sup>rd</sup> ed. Academic Press: New York; Bisswanger, H., (1994) *Enzymkinetik*, 2<sup>nd</sup> ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., Graßl, M., eds. (1983-1986) *Methods of Enzymatic Analysis*, 3<sup>rd</sup> ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's *Encyclopedia of Industrial Chemistry* (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 352-363.

- The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assays (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. *et al.* (1995) *EMBO J.* 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.

- The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, Channels and Transporters", in *Biomembranes, Molecular Structure and Function*, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.

**Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired Product**

- The effect of the genetic modification in *C. glutamicum* on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing the medium and/or the cellular component for increased production of the desired product (*i.e.*, an amino acid). Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining

- methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. *et al.*, (1987) "Applications of HPLC in Biochemistry" in:
- 5 Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm *et al.* (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 469-714, VCH: Weinheim; Belter, P.A. *et al.* (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz,
- 10 J.A. and Henry, J.D. (1988) Biochemical separations, in: Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)

In addition to the measurement of the final product of fermentation, it is also

15 possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (*e.g.*, sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and

20 growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach, P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.

25

**Example 10: Purification of the Desired Product from *C. glutamicum* Culture**

Recovery of the desired product from the *C. glutamicum* cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the

30 culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the *C. glutamicum* cells, then the cells are removed from the culture by low-speed centrifugation, and the

35 supernate fraction is retained for further purification.

The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on

5 chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.

10 techniques are described, for example, in Bailey, J.E. & Ollis, D.F. Biochemical Engineering Fundamentals, McGraw-Hill: New York (1986).

15 assay, or microbiologically. Such analysis methods are reviewed in: Patek *et al.* (1994) *Appl. Environ. Microbiol.* 60: 133-140; Malakhova *et al.* (1996) *Biotekhnologiya* 11: 27-32; and Schmidt *et al.* (1998) *Bioprocess Engineer.* 19: 67-70. Ulmann's Encyclopedia of Industrial Chemistry, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) *Biochemical Pathways: An*  
20 *Atlas of Biochemistry and Molecular Biology*, John Wiley and Sons; Fallon, A. *et al.* (1987) *Applications of HPLC in Biochemistry* in: *Laboratory Techniques in Biochemistry and Molecular Biology*, vol. 17.

### Example 11: Analysis of the Gene Sequences of the Invention

25 The comparison of sequences and determination of percent homology between  
two sequences are art-known techniques, and can be accomplished using a mathematical  
algorithm, such as the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci.*  
USA 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci.* USA  
90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST  
30 programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST  
nucleotide searches can be performed with the NBLAST program, score = 100,  
wordlength = 12 to obtain nucleotide sequences homologous to MCT nucleic acid  
molecules of the invention. BLAST protein searches can be performed with the  
XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences  
35 homologous to MCT protein molecules of the invention. To obtain gapped alignments  
for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*,  
(1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped



BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (e.g., XBLAST and NBLAST) for the specific sequence being analyzed.

Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) *Comput. Appl. Biosci.* 4: 11-17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM, described in Torelli and Robotti (1994) *Comput. Appl. Biosci.* 10:3-5; and FASTA, described in Pearson and Lipman (1988) *P.N.A.S.* 85:2444-8.

The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3.

A comparative analysis of the gene sequences of the invention with those present in Genbank has been performed using techniques known in the art (see, e.g., Bexevanis and Ouellette, eds. (1998) *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins*. John Wiley and Sons: New York). The gene sequences of the invention were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (e.g., a local alignment analysis) was performed for each of the sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (e.g., a combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the length of the query sequences by methods well-known in the art. The results of this analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP

(global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading "% homology (GAP)" are listed in the European numerical format, wherein a ',' represents a decimal point. For example, a value of "40,345" in this column represents "40.345%".

**Example 12: Construction and Operation of DNA Microarrays**

The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. *et al.* (1995) *Science* 270: 467-470; Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367; DeSaizieu, A. *et al.* (1998) *Nature Biotechnology* 16: 45-48; and DeRisi, J.L. *et al.* (1997) *Science* 278: 680-686).

DNA microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, *e.g.*, Schena, M. (1996) *BioEssays* 18(5): 427-431).

The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more *C. glutamicum* genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice and design of the 5' or 3' oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. *et al.* (1995) *Science* 270: 467-470).

Nucleic acid microarrays may also be constructed by *in situ* oligonucleotide synthesis as described by Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the

synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.

5 The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be labeled according to standard methods. In brief, nucleic acid molecules (*e.g.*, mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, *e.g.*, during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (*e.g.*, in Schena, M. *et al.* (1995) *supra*; Wodicka, L. *et al.* (1997), *supra*; and DeSaizieu A. *et al.* (1998), *supra*). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as described in Schena, M. *et al.* (1995) *supra*) and fluorescent labels may be detected, for example, by the method of Shalon *et al.* (1996) *Genome Research* 6: 639-645).

15 The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of *C. glutamicum* or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.

### 25 **Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics)**

The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed 'proteomics'. Protein populations of interest include, but are not limited to, the total protein population of *C. glutamicum* (*e.g.*, in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (*e.g.*, during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.

35 Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing

polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann *et al.* (1998) *Electrophoresis* 19: 3217-3221; Fountoulakis *et al.* (1998) *Electrophoresis* 19: 1193-1202; Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192; Antelmann *et al.* (1997) *Electrophoresis* 18: 1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.

Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (*e.g.*,  $^{35}\text{S}$ -methionine,  $^{35}\text{S}$ -cysteine,  $^{14}\text{C}$ -labelled amino acids,  $^{15}\text{N}$ -amino acids,  $^{15}\text{NO}_3$  or  $^{15}\text{NH}_4^+$  or  $^{13}\text{C}$ -labelled amino acids) in the medium of *C. glutamicum* permits the labeling of proteins from these cells prior to their separation. Similarly, fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.

Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art.

To determine the identity of any given protein, direct sequencing or other standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, *e.g.*, Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192)). The protein sequences provided herein can be used for the identification of *C. glutamicum* proteins by these techniques.

The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (*e.g.*, different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (*e.g.*, metabolic)

situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.

**Equivalents**

- 5        Those of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

TABLE 1: GENES IN THE APPLICATION

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
1	2	RXA00775	GR00205	6057	5287	PHOSPHATE TRANSPORT ATP-BINDING PROTEIN PSTB
3	4	RXA00776	GR00205	7016	6096	PHOSPHATE TRANSPORT SYSTEM PERMEASE PROTEIN PSTA
5	6	RXA00777	GR00205	8098	7034	PHOSPHATE TRANSPORT SYSTEM PERMEASE PROTEIN PSTC
7	8	RXA00774	GR00205	4546	5199	PHOSPHATE TRANSPORT SYSTEM REGULATORY PROTEIN
9	10	RXA00204	GR00032	3783	2212	RIBOSE TRANSPORT ATP-BINDING PROTEIN RBSA
11	12	RXA02438	GR00709	3236	2478	RIBOSE TRANSPORT ATP-BINDING PROTEIN RBSA
13	14	RXA00203	GR00032	2152	1241	RIBOSE TRANSPORT SYSTEM PERMEASE PROTEIN RBSC
15	16	RXA00270	GR00041	2720	1833	RIBOSE TRANSPORT SYSTEM PERMEASE PROTEIN RBSC
17	18	RXA02439	GR00709	4258	3236	RIBOSE TRANSPORT SYSTEM PERMEASE PROTEIN RBSC
19	20	RXN02994	VV0070	2	724	GLUTAMINE TRANSPORT ATP-BINDING PROTEIN GLNQ
21	22	F RXA01245	GR00360	2	1768	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)

**Lipoprotein and Lipopolysaccharide synthesis**

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
23	24	RXA00002	GR00001	2278	1595	DOLICHOL-PHOSPHATE MANNOSYL TRANSFERASE (EC 2.4.1.83) / APOLIPOPROTEIN N-ACYL TRANSFERASE (EC 2.3.1.-) / LIPOPROTEIN NLPD/LPPB HOMOLOG PRECURSOR
25	26	RXA00160	GR00024	4044	4616	Zn-binding lipoprotein
27	28	RXA00345	GR00064	90	1040	OUTER MEMBRANE LIPOPROTEIN 3 PRECURSOR
29	30	RXA00413	GR00092	3859	2963	OUTER MEMBRANE LIPOPROTEIN BLC PRECURSOR
31	32	RXA00482	GR00119	1891	18244	DOLICHOL-PHOSPHATE MANNOSYL TRANSFERASE (EC 2.4.1.83) /
33	34	RXN01164	VV0117	15894	14260	DOLICHOL-PHOSPHATE MANNOSYL TRANSFERASE (EC 2.3.1.-) /
35	36	F RXA01164	GR00332	1579	5	DOLICHOL-PHOSPHATE MANNOSYL TRANSFERASE (EC 2.4.1.83) /
37	38	RXN01168	VV0117	14224	13415	APOLIPOPROTEIN N-ACYL TRANSFERASE (EC 2.3.1.-) /
39	40	F RXA01168	GR00333	1285	566	DOLICHOL-PHOSPHATE MANNOSYL TRANSFERASE (EC 2.4.1.83) /
41	42	RXN02062	VV0222	3159	1990	APOLIPOPROTEIN N-ACYL TRANSFERASE (EC 2.3.1.-) /
43	44	F RXA02062	GR00626	3159	1990	Lipopolysaccharide N-acetylglicosaminyltransferase
45	46	RXA02222	GR00661	9420	9794	Lipopolysaccharide N-acetylglicosaminyltransferase
47	48	RXA02313	GR00665	5812	4592	PUTATIVE HOST CELL SURFACE-EXPOSED LIPOPROTEIN
49	50	RXA02491	GR00720	902	2155	Lipopolysaccharide N-acetylglicosaminyltransferase
51	52	RXN02595	VV0098	11098	9935	Lipopolysaccharide N-acetylglicosaminyltransferase
53	54	F RXA02595	GR00741	19052	19702	Lipopolysaccharide N-acetylglicosaminyltransferase
55	56	RXA02616	GR00745	598	1308	LIPOPROTEIN NLPD PRECURSOR
57	58	RXA02627	GR00747	2981	2139	DTXR/IRON-REGULATED LIPOPROTEIN PRECURSOR
59	60	RXA02650	GR00752	1460	2038	LIPOPROTEIN SIGNAL PEPTIDASE (EC 3.4.23.36)
61	62	RXA01094	GR00306	2703	1756	PROLIPOPROTEIN DIACYLGLYCERYL TRANSFERASE (EC 2.4.99.-)

006670324 - 00667000

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
63	64	RXN00934	VV0171	15181	14099	(AE000805) LPS biosynthesis RfbU related protein [Methanobacterium thermoautotrophicum]
65	66	F RXA00934	GR00253	6635	6047	(AE000805) LPS biosynthesis RfbU related protein [Methanobacterium thermoautotrophicum]
67	68	RXA02605	GR00742	11557	12051	ANTIGEN 85-B PRECURSOR

**ABC-Transporter**

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
69	70	RXN00525	VV0079	26304	27566	Hypothetical ABC Transporter Permease Protein
71	72	F RXA00525	GR00136	664	5	Hypothetical ABC Transporter Permease Protein
73	74	F RXA00556	GR00146	1	594	Hypothetical ABC Transporter Permease Protein
75	76	RXA02750	GR00764	5079	5894	Hypothetical ABC Transporter Permease Protein
77	78	RXN02096	VV0126	20444	22135	Hypothetical ABC Transporter Permease Protein
79	80	F RXA02096	GR00629	15458	16774	Hypothetical ABC Transporter Permease Protein
81	82	RXA02562	GR00732	796	1515	PUTATIVE ABC TRANSPORTER
83	84	RXA00950	GR00260	173	1078	similar to ABC transporter (ATP-binding protein) START CODON GTG
85	86	RXA02119	GR00636	4222	2582	similar to ABC transporter (ATP-binding protein)
87	88	RXA01185	GR00338	2451	1594	ATP-BINDING PROTEIN
89	90	RXN00412	VV0086	53923	52844	Hypothetical Amino Acid ABC Transporter ATP-Binding Protein
91	92	F RXA00412	GR00092	2764	1685	ATP-BINDING PROTEIN ABC
93	94	RXN02925	VV0104	543	2759	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)
95	96	RXN00939	VV0079	45152	43917	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)
97	98	F RXA00939	GR00256	1501	1334	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)
99	100	RXN01323	VV0082	4321	6585	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)
101	102	F RXA01323	GR00385	1175	3439	similar to heavy metal-transporting ATPase
103	104	RXN00702	VV0005	12478	10772	COBAL T TRANSPORT ATP-BINDING PROTEIN CBIO
105	106	F RXA00702	GR00182	2165	846	COBAL T TRANSPORT ATP-BINDING PROTEIN CBIO
107	108	RXN00828	VV0180	1376	1828	COBAL T TRANSPORT ATP-BINDING PROTEIN CBIO
109	110	F RXA00828	GR00223	1687	1319	COBAL T TRANSPORT ATP-BINDING PROTEIN CBIO
111	112	RXN03020	VV0139	606	4	GLUTAMINE TRANSPORT ATP-BINDING PROTEIN GLNQ
113	114	RXN00726	VV0188	1	591	GLUTAMINE TRANSPORT ATP-BINDING PROTEIN GLNQ
115	116	RXN02570	VV0101	11699	12340	MALTOSE TRANSPORT SYSTEM PERMEASE PROTEIN MALF
117	118	RXN02354	VV0095	473	1306	MALTOSE TRANSPORT SYSTEM PERMEASE PROTEIN MALG
119	120	F RXA02354	GR00682	473	1261	MALTOSE TRANSPORT SYSTEM PERMEASE PROTEIN MALG
121	122	RXN00001	VV0196	4023	2896	MALTOSE/MALTODEXTRIN TRANSPORT ATP-BINDING PROTEIN MALK
123	124	F RXA00001	GR00001	1386	259	SN-GLYCEROL-3-PHOSPHATE TRANSPORT ATP-BINDING PROTEIN UGPC
125	126	RXN02356	VV0051	1868	873	MALTOSE/MALTODEXTRIN TRANSPORT ATP-BINDING PROTEIN MALK
127	128	RXN02455	VV0196	1273	5	MALTOSE-BINDING PROTEIN PRECURSOR
129	130	RXN02795	VV0176	29237	27801	OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN APPF
131	132	F RXA02795	GR00778	3	1097	OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN APPF
133	134	RXN01939	VV0139	22695	20965	OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN OPDP
135	136	F RXA00761	GR00203	8530	9120	OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN OPDP
137	138	F RXA01939	GR00556	2042	1440	OLIGOPEPTIDE TRANSPORT ATP-BINDING PROTEIN OPDP

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
139	140	RXN00759	VV0139	24645	23722	OLIGOPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN OPPB
141	142	F RXA00759	GR00203	6580	7503	OLIGOPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN OPPB
143	144	RXN00431	VV0112	8887	8199	O-ANTIGEN EXPORT SYSTEM ATP-BINDING PROTEIN RFBE
145	146	F RXA00431	GR00099	119	793	ABCA PROTEIN two-component ABC transporter involved in the metabolism of two wall terchoic acids
147	148	RXN00732	VV0132	1	1647	PROBABLE TRANSPORT ATP-BINDING PROTEIN MSBA
149	150	F RXA00732	GR00196	826	5	PROBABLE TRANSPORT ATP-BINDING PROTEIN MSBA
151	152	F RXA00734	GR00197	863	411	Hypothetical ABC Transporter ATP-Binding Protein
153	154	RXN01808	VV0216	3	1151	PUTATIVE ABC TRANSPORTER
155	156	F RXA01808	GR00509	8993	7875	PUTATIVE ABC TRANSPORTER
157	158	RXN02975	VV0231	252	4	Hypothetical ABC Transporter ATP-Binding Protein
159	160	RXN03116	VV0090	38675	38675	MALTOSE/MALTODEXTRIN TRANSPORT ATP-BINDING PROTEIN MALK
161	162	RXN03108	VV0077	5535	5801	NITRATE TRANSPORT ATP-BINDING PROTEIN NRTD
163	164	RXN03129	VV0122	24042	22819	SN-GLYCEROL-3-PHOSPHATE TRANSPORT ATP-BINDING PROTEIN UGPC
165	166	F RXA01890	GR00541	874	155	SN-GLYCEROL-3-PHOSPHATE TRANSPORT ATP-BINDING PROTEIN UGPC
167	168	RXN02945	VV0180	492	1424	COBALI TRANSPORT ATP-BINDING PROTEIN CBIO

## Other transporters

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
169	170	RXA01247	GR00361	256	489	COPPER/POTASSIUM-TRANSPORTING ATPASE B (EC 3.6.1.36)
171	172	RXN00099	VV0129	18876	17704	CYANATE TRANSPORT PROTEIN CYNX
173	174	F RXA00099	GR00014	8172	9344	CYANATE TRANSPORT PROTEIN CYNX
175	176	RXA00634	GR00166	3732	5114	D-/TRIPEPTIDE TRANSPORTER
177	178	RXA02451	GR00710	3484	5007	D-/TRIPEPTIDE TRANSPORTER
179	180	RXA02394	GR00697	1895	585	DICARBOXYLATE TRANSPORTER
181	182	RXA01012	GR00288	3748	2108	DIPEPTIDE TRANSPORT ATP-BINDING PROTEIN DPPD
183	184	RXA02660	GR00753	548	1186	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPB
185	186	RXA02661	GR00753	1239	1457	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPB
187	188	RXA02034	GR00619	1787	822	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPB
189	190	RXA01013	GR00288	4549	3755	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPC
191	192	RXN02933	VV0176	30042	29233	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPC
193	194	F RXA02033	GR00619	800	12	DIPEPTIDE TRANSPORT SYSTEM PERMEASE PROTEIN DPPC
195	196	RXA01006	GR00287	862	5	DIPEPTIDE TRANSPORTER PROTEIN DPPB
197	198	RXA02312	GR00665	4459	3101	D-SERINE/D-ALANINE/GLYCINE TRANSPORTER
199	200	RXA00090	GR00013	6644	7762	FERRIC ANGUIBACTIN TRANSPORT SYSTEM PERMEASE PROTEIN FATC
201	202	RXA00089	GR00013	5656	6654	FERRIC ANGUIBACTIN TRANSPORT SYSTEM PERMEASE PROTEIN FATD
203	204	RXN01285	VV0215	1780	1055	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
205	206	F RXA01285	GR00371	3	545	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
207	208	RXA02728	GR00761	184	996	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
209	210	RXN03080	VV0045	1670	2449	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
211	212	F RXA02864	GR10007	2806	2027	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
213	214	RXN00523	VV0194	1363	338	FERRIC ENTEROBACTIN TRANSPORT ATP-BINDING PROTEIN FEPC
215	216	F RXA00523	GR00135	30	779	FERRIC ENTEROBACTIN TRANSPORT PROTEIN FEPC





<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
305	306	RXN01298	VV0116	2071	1142	POTENTIAL STARCH DEGRADATION PRODUCTS TRANSPORT SYSTEM
307	308	F RXA01298	GR00374	1254	862	PERMEASE PROTEIN AMYD
309	310	F RXA02422	GR00705	8200	8634	POTENTIAL STARCH DEGRADATION PRODUCTS TRANSPORT SYSTEM
311	312	RXN02515	VV0087	962	1717	PERMEASE PROTEIN AMYD
313	314	F RXA02515	GR00723	964	1719	Hypothetical ABC Transporter ATP-Binding Protein
315	316	RXN01995	VV0182	2139	3476	PROBABLE ATP-DEPENDENT TRANSPORTER YCF16
317	318	F RXA01995	GR00584	1362	2015	PUTATIVE 3-(3-HYDROXYPHENYL) PROPIONATE TRANSPORT PROTEIN
319	320	RXA01188	GR00339	1585	482	PUTATIVE 3-(3-HYDROXYPHENYL) PROPIONATE TRANSPORT PROTEIN
321	322	RXA01972	GR00569	2116	1523	QUATERNARY AMINE TRANSPORTER
323	324	RXA00311	GR00053	1592	738	SHIKIMATE TRANSPORTER
325	326	RXA00312	GR00053	2066	1641	SHIKIMATE TRANSPORTER
327	328	RXN01411	VV0050	26015	26779	SHIKIMATE TRANSPORTER
329	330	F RXA01411	GR00412	1	327	SHIKIMATE TRANSPORTER
331	332	RXA01900	GR00544	2822	4120	SHIKIMATE TRANSPORTER
333	334	RXA02507	GR00720	19760	21160	SHIKIMATE TRANSPORTER
335	336	RXA00445	GR00107	21	932	SHIKIMATE TRANSPORTER
337	338	RXA02353	GR00682	6	473	SHIKIMATE TRANSPORTER
339	340	RXA01297	GR00374	826	29	SHIKIMATE TRANSPORTER
341	342	RXS00088	VV0027	2	877	SHIKIMATE TRANSPORTER
343	344	RXS00372	VV0226	3456	2380	SHIKIMATE TRANSPORTER
345	346	RXS02590	VV0098	15313	16248	SHIKIMATE TRANSPORTER
347	348	RXS00758	VV0139	26428	24827	SHIKIMATE TRANSPORTER
349	350	RXS01346	VV0123	5120	6694	SHIKIMATE TRANSPORTER
351	352	RXS00912	VV0339	552	280	SHIKIMATE TRANSPORTER
353	354	RXS00453	VV0076	1173	3521	SHIKIMATE TRANSPORTER
355	356	RXS00932	VV0171	13120	13593	SHIKIMATE TRANSPORTER
357	358	RXS00479	VV0086	42008	39819	SHIKIMATE TRANSPORTER
359	360	RXS02586	VV0098	19854	20123	SHIKIMATE TRANSPORTER
361	362	RXS02587	VV0098	17807	19897	SHIKIMATE TRANSPORTER
363	364	RXS03042	VV0018	2440	1835	SHIKIMATE TRANSPORTER
365	366	RXS03075	VV0042	2491	3216	SHIKIMATE TRANSPORTER
367	368	RXS03124	VV0108	4	963	SHIKIMATE TRANSPORTER
369	370	RXS03125	VV0108	972	1142	SHIKIMATE TRANSPORTER

## Channel Proteins

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
371	372	RXA00596	GR00159	335	787	potassium efflux system protein phae
373	374	RXA02079	GR00628	9034	9648	CATION EFFLUX SYSTEM PROTEIN CZCD

09603024-052300

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
375	376	RXA01303	GR00376	1724	390	NITRITE EXTRUSION PROTEIN
377	378	RXA02079	GR00628	9034	9648	CATION EFFLUX SYSTEM PROTEIN CZCD
379	380	RXN00832	VV0180	3133	4182	CALCIUM/PROTON ANTIporter
381	382	F RXA00832	GR00224	2239	1685	CALCIUM/PROTON ANTIporter
383	384	RXN00378	VV0223	8027	5418	Cation transport ATPases
385	386	F RXA00378	GR00081	3271	1499	Cation transport ATPases
387	388	RXA00942	GR00257	2406	2203	CATION-TRANSPORTING ATPASE PACS (EC 3.6.1.-)
389	390	RXN01338	VV0032	2	1903	CATION-TRANSPORTING ATPASE PACS (EC 3.6.1.-)
391	392	F RXA01338	GR00389	6964	5087	CATION-TRANSPORTING ATPASE PACS (EC 3.6.1.-)
393	394	RXA01625	GR00452	3850	3650	CATION-TRANSPORTING ATPASE PACS (EC 3.6.1.-)
395	396	RXA02220	GR00651	3205	5880	CATION-TRANSPORTING ATPASE PMA1 (EC 3.6.1.-)
397	398	RXN00980	VV0149	2635	4428	CATION-TRANSPORTING P-TYPE ATPASE B (EC 3.6.1.-)
399	400	F RXA00980	GR00276	2648	3286	CATION-TRANSPORTING P-TYPE ATPASE B (EC 3.6.1.-)
401	402	RXN02348	VV0078	6027	7910	CUP SYSTEM POTASSIUM UPTAKE PROTEIN
403	404	F RXA02348	GR00677	1719	586	CUP SYSTEM POTASSIUM UPTAKE PROTEIN
405	406	F RXA02344	GR00676	682	5	CUP SYSTEM POTASSIUM UPTAKE PROTEIN
407	408	RXN00960	VV0075	1139	105	PROTON/SODIUM-GLUTAMATE SYMPORT PROTEIN
409	410	F RXA00960	GR00266	563	105	PROTON/SODIUM-GLUTAMATE SYMPORT PROTEIN
411	412	RXA01070	GR00299	2089	704	PROTON/SODIUM-GLUTAMATE SYMPORT PROTEIN
413	414	RXA02628	GR00748	6	410	LARGE CONDUCTANCE MECHANOSENSITIVE CHANNEL
415	416	RXN03164	VV0277	1586	2455	POTASSIUM CHANNEL BETA SUBUNIT
417	418	F RXA01395	GR00408	6106	5021	POTASSIUM CHANNEL BETA SUBUNIT

### Other membrane proteins

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
419	420	RXA02597	GR00742	2329	542	OUTER MEMBRANE USHER PROTEIN FIMC PRECURSOR
421	422	RXA01454	GR00420	270	4	Integral membrane protein
423	424	RXA01455	GR00420	745	284	Integral membrane protein
425	426	RXA02684	GR00754	8923	8060	MEMBRANE-BOUND PROTEIN LYTR
427	428	RXN02391	VV0176	3525	3923	(U59457) Pseudomonas aeruginosa ankryn (ankB) gene, complete cds
429	430	RXN02549	VV0098	3165	5867	[Pseudomonas aeruginosa]
431	432	RXN00808	VV0009	63243	64700	PUTATIVE INTEGRAL MEMBRANE PROTEIN
433	434	RXS01425	VV0050	2679	3563	60 KD INNER-MEMBRANE PROTEIN
435	436	RXS01658	VV0010	44183	42351	membrane protein
437	438	RXS01677	VV0179	12923	12180	membrane protein
439	440	RXS02932	VV0176	23391	24362	Membrane Spanning Protein
441	442	F RXA02402	GR00700	747	4	(AF027868) putative transporter [Bacillus subtilis]
443	444	RXS00654	VV0109	6289	5024	60 KD INNER-MEMBRANE PROTEIN

06603034\_06603073

TABLE 2: GENES IDENTIFIED FROM GENBANK

GenBank™ Accession No.	Gene Name	Gene Function	Reference
A09073	ppg	Phosphoenol pyruvate carboxylase	Bachmann, B. et al. "DNA fragment coding for phosphoenolpyruvate carboxylase, recombinant DNA carrying said fragment, strains carrying the recombinant DNA and method for producing L-aminino acids using said strains." Patent: EP 0358940-A 3 03/21/90
A45579, A45581, A45583, A45585 A45587		Threonine dehydratase	Moeckel, B. et al. "Production of L-isoleucine by means of recombinant micro-organisms with deregulated threonine dehydratase," Patent: WO 9519442-A 5 07/20/95
AB003132	murC; ftsQ; ftsZ		Kobayashi, M. et al. "Cloning, sequencing, and characterization of the ftsZ gene from corynebacterium bacteria," <i>Biochem. Biophys. Res. Commun.</i> , 236(2):383-388 (1997)
AB015023	murC; ftsQ		Wachi, M. et al. "A murC gene from Corynebacterium bacteria," <i>Appl. Microbiol. Biotechnol.</i> , 51(2):223-228 (1999)
AB018530	dsr		Kimura, E. et al. "Molecular cloning of a novel gene, dsr, which rescues the detergent sensitivity of a mutant derived from <i>Brevibacterium lactofermentum</i> ," <i>Biosci. Biotechnol. Biochem.</i> , 60(10):1565-1570 (1996)
AB018531	dsr1; dsr2		
AB020624	murI	D-glutamate racemase	
AB023377	tkt	transketolase	
AB024708	glbB; gltD	Glutamine 2-oxoglutarate aminotransferase large and small subunits	
AB025424	acn	aconitase	
AB027714	rep	Replication protein	
AB027715	rep; aad	Replication protein; aminoglycoside adenylyltransferase	
AF005242	argC	N-acetylglutamate-5-semialdehyde dehydrogenase	
AF005635	glnA	Glutamine synthetase	
AF030405	hisF	cyclase	
AF030520	argG	Argininosuccinate synthetase	
AF031518	argF	Ornithine carbamolytransferase	
AF036932	aroD	3-dehydroquinate dehydratase	

00000000 00000000

GenBank™ Accession No.	Gene Name	Gene Function	Reference
AF038548	pyc	Pyruvate carboxylase	
AF038651	deiA; apt; rel	Dipeptide-binding protein; adenine phosphoribosyltransferase; GTP pyrophosphokinase	Wehmeier, L. et al. "The role of the <i>Corynebacterium glutamicum</i> rel gene in (p)ppGpp metabolism," <i>Microbiology</i> , 144:1853-1862 (1998)
AF041436	argR	Arginine repressor	
AF045998	impA	Inositol monophosphate phosphatase	
AF048764	argH	Argininosuccinate lyase	
AF049897	argC; argJ; argB; argD; argF; argR; argG; argH	N-acetylglutanylphosphate reductase; ornithine acetyltransferase; N-acetylglutamate kinase; acetylornithine transaminase; ornithine carbamoyltransferase; arginine repressor; argininosuccinate synthase; argininosuccinate lyase	
AF050109	inhA	Enoyl-acyl carrier protein reductase	
AF050166	hisG	ATP phosphoribosyltransferase	
AF051846	hisA	Phosphoribosylformimino-5-amino-1-phosphoribosyl-4-imidazolecarboxamide isomerase	
AF052652	metA	Homoserine O-acetyltransferase	Park, S. et al. "Isolation and analysis of metA, a methionine biosynthetic gene encoding homoserine acetyltransferase in <i>Corynebacterium glutamicum</i> ," <i>Mol. Cells</i> , 8(3):286-294 (1998)
AF053071	arob	Dehydroquinate synthetase	
AF060558	hisH	Glutamine amidotransferase	
AF06704	hisE	Phosphoribosyl-ATP-pyrophosphohydrolase	
AF114233	aroA	5-enolpyruvylshikimate 3-phosphate synthase	
AF116184	pand	L-aspartate-alpha-decarboxylase precursor	Dusch, N. et al. "Expression of the <i>Corynebacterium glutamicum</i> pand gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in <i>Escherichia coli</i> ," <i>Appl. Environ. Microbiol.</i> , 65(4):1530-1539 (1999)

06673024.0623077



GenBank™ Accession No.	Gene Name	Gene Function	Reference
D84102	odhA	2-oxoglutarate dehydrogenase	Usuda, Y. et al. "Molecular cloning of the <i>Corynebacterium glutamicum</i> (Brevibacterium lactofermentum AJ12036) odhA gene encoding a novel type of 2-oxoglutarate dehydrogenase," <i>Microbiology</i> , 142:3347-3354 (1996)
E01358	hdh; hk	Homoserine dehydrogenase; homoserine kinase	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 1 10/12/87
E01359		Upstream of the start codon of homoserine kinase gene	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 2 10/12/87
U01375		Tryptophan operon	
U01376	trpL; trpE	Leader peptide; anthranilate synthase	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E01377		Promoter and operator regions of tryptophan operon	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E03937		Biotin-synthase	Hatakeyama, K. et al. "DNA fragment containing gene capable of coding biotin synthetase and its utilization," Patent: JP 1992278088-A 1 10/02/92
E04040		Diamino pelargonic acid aminotransferase	Kohama, K. et al. "Gene coding diaminopelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04041		Deshiobiotinsynthetase	Kohama, K. et al. "Gene coding diaminopelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04307		Flavum aspartase	Kunusu, Y. et al. "Gene DNA coding aspartase and utilization thereof," Patent: JP 1993030977-A 1 02/09/93
U01376		Isocitric acid lyase	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04377		Isocitric acid lyase N-terminal fragment	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04484		Prephenate dehydratase	Sotouchi, N. et al. "Production of L-phenylalanine by fermentation," Patent: JP 1993076352-A 2 03/30/93
E05108		Aspartokinase	Fugono, N. et al. "Gene DNA coding Aspartokinase and its use," Patent: JP 1993184366-A 1 07/27/93
E05112		Dihydro-dipicolinate synthetase	Hatakeyama, K. et al. "Gene DNA coding dihydrodipicolinic acid synthetase and its use," Patent: JP 1993184371-A 1 07/27/93

GenBank™ Accession No.	Gene Name	Gene Function	Reference
E05776		Diaminopimelic acid dehydrogenase	Kobayashi, M. et al. "Gene DNA coding Diaminopimelic acid dehydrogenase and its use," Patent: JP 1993284970-A 1 11/02/93
E05779		Threonine synthase	Kohama, K. et al. "Gene DNA coding threonine synthase and its use," Patent: JP 1993284972-A 1 11/02/93
E06110		Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A 1 12/27/93
6111		Mutated Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A 1 12/27/93
E06146		Acetohydroxy acid synthetase	Inui, M. et al. "Gene capable of coding Acetohydroxy acid synthetase and its use," Patent: JP 1993344893-A 1 12/27/93
E06825		Aspartokinase	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E06826		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E06827		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A 1 03/08/94
E07701	secY		Homo, N. et al. "Gene DNA participating in integration of membraneous protein to membrane," Patent: JP 1994169780-A 1 06/21/94
E08177		Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08178, E08179, E08180, E08181, E08182		Feedback inhibition-released Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A 1 09/20/94
E08232		Acetohydroxy-acid isomerase	Inui, M. et al. "Gene DNA coding acetohydroxy acid isomerase," Patent: JP 1994277067-A 1 10/04/94
E08234	secE		Asai, Y. et al. "Gene DNA coding for translocation machinery of protein," Patent: JP 1994277073-A 1 10/04/94
E08643		FT aminotransferase and deshydrobiotin synthetase promoter region	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95
E08646		Biotin synthetase	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A 1 02/03/95



GenBank™ Accession No.	Gene Name	Gene Function	Reference
E08649		Aspartase	Kohama, K. et al "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031478-A 1 02/03/95
E08900		Dihydropicolinate reductase	Madori, M. et al. "DNA fragment containing gene coding Dihydropicolinate acid reductase and utilization thereof," Patent: JP 1995075578-A 1 03/20/95
E08901		Diaminopimelic acid decarboxylase	Madori, M. et al. "DNA fragment containing gene coding Diaminopimelic acid decarboxylase and utilization thereof," Patent: JP 1995075579-A 1 03/20/95
E2594		Serine hydroxymethyltransferase	Hatakeyama, K. et al. "Production of L-tryptophan," Patent: JP 1997028391-A 1 02/04/97
E12760, E12759, E12758		transposase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12764		Arginyl-tRNA synthetase; diaminopimelic acid decarboxylase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12767		Dihydropicolinic acid synthetase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12770		aspartokinase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12773		Dihydropicolinic acid reductase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E13655		Glucose-6-phosphate dehydrogenase	Hatakeyama, K. et al. "Glucose-6-phosphate dehydrogenase and DNA capable of coding the same," Patent: JP 1997224661-A 1 09/02/97
L01508	IlvA	Threonine dehydratase	Moeckel, B. et al. "Functional and structural analysis of the threonine dehydratase of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 174:8065-8072 (1992)
E07603	EC 4.2.1.15	3-deoxy-D-arabinoheptulosonate-7-phosphate synthase	Chen, C. et al. "The cloning and nucleotide sequence of <i>Corynebacterium glutamicum</i> 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase gene," <i>FEMS Microbiol. Lett.</i> , 107:223-230 (1993)
L09232	IlvB; ilvN; ilvC	Acetohydroxy acid synthase large subunit; Acetohydroxy acid synthase small subunit; Acetohydroxy acid isomerase	Keilhauer, C. et al. "Isolucine synthesis in <i>Corynebacterium glutamicum</i> : molecular analysis of the ilvB-ilvN-ilvC operon," <i>J. Bacteriol.</i> , 175(17):5595-5603 (1993)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
L18874	ptsM	Phosphoenolpyruvate sugar phosphotransferase	Fouet, A et al. "Bacillus subtilis sucrose-specific enzyme II of the phosphotransferase system: expression in Escherichia coli and homology to enzymes II from enteric bacteria," <i>PNAS USA</i> , 84(24):8773-8777 (1987); Lee, J.K. et al. "Nucleotide sequence of the gene encoding the Corynebacterium glutamicum mannose enzyme II and analyses of the deduced protein sequence," <i>FEMS Microbiol. Lett.</i> , 119(1-2):137-145 (1994)
L27123	aceB	Malate synthase	Lee, H-S. et al. "Molecular characterization of aceB, a gene encoding malate synthase in Corynebacterium glutamicum," <i>J. Microbiol. Biotechnol.</i> , 4(4):256-263 (1994)
L27126		Pyruvate kinase	Jetten, M. S. et al. "Structural and functional analysis of pyruvate kinase from Corynebacterium glutamicum," <i>Appl. Environ. Microbiol.</i> , 60(7):2501-2507 (1994)
L28760	aceA	Isocitrate lyase	
L35906	dxr	Diphtheria toxin repressor	Oguiza, J.A. et al. "Molecular cloning, DNA sequence analysis, and characterization of the Corynebacterium diphtheriae dxr from Brevibacterium lactofermentum," <i>J. Bacteriol.</i> , 177(2):465-467 (1995)
M13774		Prephenate dehydratase	Follettie, M.T. et al. "Molecular cloning and nucleotide sequence of the Corynebacterium glutamicum pheA gene," <i>J. Bacteriol.</i> , 167:695-702 (1986)
M16175	5S rRNA		Park, Y-H. et al. "Phylogenetic analysis of the coryneform bacteria by 5S rRNA sequences," <i>J. Bacteriol.</i> , 169:1801-1806 (1987)
M16663	tpE	Anthraniolate synthase, 5' end	Sano, K. et al. "Structure and function of the tp operon control regions of Brevibacterium lactofermentum, a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16664	tpA	Tryptophan synthase, 3' end	Sano, K. et al. "Structure and function of the tp operon control regions of Brevibacterium lactofermentum, a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M25819		Phosphoenolpyruvate carboxylase	O'Regan, M. et al. "Cloning and nucleotide sequence of the Phosphoenolpyruvate carboxylase-coding gene of Corynebacterium glutamicum ATCC13032," <i>Gene</i> , 77(2):237-251 (1989)
M85106		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)

116603034 : 01633000

GenBank™ Accession No.	Gene Name	Gene Function	Reference
M85107, M85108		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M89931	aecD; brnQ; yhbW	Beta C-S lyase; branched-chain amino acid uptake carrier; hypothetical protein yhbW	Rosol, I. et al. "The Corynebacterium glutamicum aecD gene encodes a C-S lyase with alpha, beta-elimination activity that degrades aminothyllysine," <i>J. Bacteriol.</i> , 174(9):2968-2977 (1992); Tauch, A. et al. "Isoleucine uptake in Corynebacterium glutamicum ATCC 13032 is directed by the brnQ gene product," <i>Arch. Microbiol.</i> , 169(4):303-312 (1998)
9299	trp	Leader gene (promoter)	Herry, D.M. et al. "Cloning of the trp gene cluster from a tryptophan-hyperproducing strain of Corynebacterium glutamicum: identification of a mutation in the trp leader sequence," <i>Appl. Environ. Microbiol.</i> , 59(3):791-799 (1993)
U11545	trpD	Anthranilate phosphoribosyltransferase	O'Gara, J.P. and Dunican, I.K. (1994) Complete nucleotide sequence of the Corynebacterium glutamicum ATCC 21850 trpD gene." Thesis, Microbiology Department, University College Galway, Ireland.
U13922	cglIM; cglIR; cglJIR	Putative type II 5-cytosine methyltransferase; putative type II restriction endonuclease; putative type I or type III restriction endonuclease	Schafer, A. et al. "Cloning and characterization of a DNA region encoding a stress-sensitive restriction system from Corynebacterium glutamicum ATCC 13032 and analysis of its role in intergeneric conjugation with Escherichia coli," <i>J. Bacteriol.</i> , 176(23):7309-7319 (1994); Schafer, A. et al. "The Corynebacterium glutamicum cglIM gene encoding a 5-cytosine in an McrBC-deficient Escherichia coli strain," <i>Gene</i> , 203(2):95-101 (1997)
U14965	recA		
U31224	ppx		Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31225	proC	L-proline: NADP+ 5-oxidoreductase	Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31230	obg; proB; unkdh	?;gamma glutamyl kinase; similar to D-isomer specific 2-hydroxyacid dehydrogenases	Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)

70603034 : 062307

GenBank™ Accession No.	Gene Name	Gene Function	Reference
U31281	bioB	Biotin synthase	Serebriiskii, I.G., "Two new members of the bio B superfamily: Cloning, sequencing and expression of bio B genes of <i>Methylobacillus flagellatum</i> and <i>Corynebacterium glutamicum</i> ," <i>Gene</i> , 175:15-22 (1996)
U35023	thtR, accBC	Thiosulfate sulfurtransferase; acyl CoA carboxylase	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene encoding a two-domain protein similar to biotin carboxylases and biotin-carboxyl-carrier proteins," <i>Arch. Microbiol.</i> , 166(2):76-82 (1996)
U43535	cmr	Multidrug resistance protein	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene conferring multidrug resistance in the heterologous host <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , 179(7):2449-2451 (1997)
U43536	clpB	Heat shock ATP-binding protein	
U53587	aphA-3	3'5'-aminoglycoside phosphotransferase	
U89648		<i>Corynebacterium glutamicum</i> unidentified sequence involved in histidine biosynthesis, partial sequence	
X04960	trpA; trpB; trpC; trpD; trpE; trpG; trpL	Tryptophan operon	Matsui, K. et al. "Complete nucleotide and deduced amino acid sequences of the <i>Brevibacterium lactofermentum</i> tryptophan operon," <i>Nucleic Acids Res.</i> , 14(24):10113-10114 (1986)
X07563	lys A	DAP decarboxylase (meso-diaminopimelate decarboxylase, EC 4.1.1.20)	Yeh, P. et al. "Nucleic sequence of the lysA gene of <i>Corynebacterium glutamicum</i> and possible mechanisms for modulation of its expression," <i>Mol. Gen. Genet.</i> , 212(1):112-119 (1988)
X14234	EC 4.1.1.31	Phosphoenolpyruvate carboxylase	Eikmanns, B.J. et al. "The Phosphoenolpyruvate carboxylase gene of <i>Corynebacterium glutamicum</i> : Molecular cloning, nucleotide sequence, and expression," <i>Mol. Gen. Genet.</i> , 218(2):330-339 (1989); Lepintec, L. et al. "Sorghum Phosphoenolpyruvate carboxylase gene family: structure, function and molecular evolution," <i>Plant. Mol. Biol.</i> , 21 (3):487-502 (1993)
X7313	fdA	Fructose-bisphosphate aldolase	Von der Osten, C.H. et al. "Molecular cloning, nucleotide sequence and fine-structural analysis of the <i>Corynebacterium glutamicum</i> fdA gene: structural comparison of C. glutamicum fructose-1, 6-bisphosphate aldolase to class I and class II aldolases," <i>Mol. Microbiol.</i>
X53993	dapA	L-2, 3-dihydrodipicolinate synthetase (EC 4.2.1.52)	Bonnasse, S. et al. "Nucleic sequence of the dapA gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 18(21):6421 (1990)

Table 2, Page 10

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X66078	copI	PSI protein	Joliff, G. et al. "Cloning and nucleotide sequence of the cspI gene encoding PSI, one of the two major secreted proteins of <i>Corynebacterium glutamicum</i> : The deduced N-terminal region of PSI is similar to the Mycobacterium antigen 85 complex," <i>Mol. Microbiol.</i> , 6(16):2349-2362 (1992)
X66112	glt	Citrate synthase	Elkmanns, B.J. et al. "Cloning sequence, expression and transcriptional analysis of the <i>Corynebacterium glutamicum</i> gltA gene encoding citrate synthase," <i>Microbiol.</i> , 140:1817-1828 (1994)
X7737 X9103	dapB csp2	Dihydrodipicolinate reductase Surface layer protein PS2	Peyret, J.L. et al. "Characterization of the cspB gene encoding PS2, an ordered surface-layer protein in <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 9(1):97-109 (1993)
X69104		IS3 related insertion element	Bonamy, C. et al. "Identification of IS1206, a <i>Corynebacterium glutamicum</i> IS3-related insertion sequence and phylogenetic analysis," <i>Mol. Microbiol.</i> , 14(3):571-581 (1994)
X70959	leuA	Isopropylmalate synthase	Patek, M. et al. "Leucine synthesis in <i>Corynebacterium glutamicum</i> : enzyme activities, structure of leuA, and effect of leuA inactivation on lysine synthesis," <i>Appl. Environ. Microbiol.</i> , 60(1):133-140 (1994)
X71489	icd	Isocitrate dehydrogenase (NADP+)	Eikmanns, B.J. et al. "Cloning sequence analysis, expression, and inactivation of the <i>Corynebacterium glutamicum</i> icd gene encoding isocitrate dehydrogenase and biochemical characterization of the enzyme," <i>J. Bacteriol.</i> , 177(3):774-782 (1995)
X72855	GDHA	Glutamate dehydrogenase (NADP+)	
X75083, X70584	mtrA	5-methyltryptophan resistance	Heery, D.M. et al. "A sequence from a tryptophan-hyperproducing strain of <i>Corynebacterium glutamicum</i> encoding resistance to 5-methyltryptophan," <i>Biochem. Biophys. Res. Commun.</i> , 201(3):1255-1262 (1994)
X75085	recA		Fitzpatrick, R. et al. "Construction and characterization of recA mutant strains of <i>Corynebacterium glutamicum</i> and <i>Brevibacterium lactofermentum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 42(4):575-580 (1994)
X75504	aceA, thiX	Partial Isocitrate lyase, ?	Reinscheid, D.J. et al. "Characterization of the isocitrate lyase gene from <i>Corynebacterium glutamicum</i> and biochemical analysis of the enzyme," <i>J. Bacteriol.</i> , 176(12):3474-3483 (1994)
X76875		ATPase beta-subunit	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)

BGI-131CP

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X77034	tuf	Elongation factor Tu	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes." <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X77384	recA		Billman-Jacobe, H. "Nucleotide sequence of a recA gene from <i>Corynebacterium glutamicum</i> ." <i>DNA Seq.</i> 4(6):403-404 (1994)
X78491	aceB	Malate synthase	Reinscheid, D.J. et al. "Malate synthase from <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase: sequence analysis," <i>Microbiology</i> , 140:3099-3108 (1994)
X0629	16S rDNA	16S ribosomal RNA	Raney, F.A. et al. "Phylogenetic analysis of the genera <i>Rhodococcus</i> and <i>Norcardia</i> and evidence for the evolutionary origin of the genus <i>Norcardia</i> from within the radiation of <i>Rhodococcus</i> species," <i>Microbiol.</i> , 141:523-528 (1995)
X81191	gluA; gluB; gluC; gluD	Glutamate uptake system	Kronmeyer, W. et al. "Structure of the gluABCD cluster encoding the glutamate uptake system of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 177(5):1152-1158 (1995)
X81379	dapE	Succinylidiaminopimelate desuccinylase	Wehrmann, A. et al. "Analysis of different DNA fragments of <i>Corynebacterium glutamicum</i> complementing dapE of <i>Escherichia coli</i> ," <i>Microbiology</i> , 40:3349-56 (1994)
X82061	16S rDNA	16S ribosomal RNA	Ruimy, R. et al. "Phylogeny of the genus <i>Corynebacterium</i> deduced from analyses of small-subunit ribosomal DNA sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):740-746 (1995)
X82928	asd; lysC	Aspartate-semialdehyde dehydrogenase; ?	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X82929	proA	Gamma-glutamyl phosphate reductase	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X84257	16S rDNA	16S ribosomal RNA	Pascal, C. et al. "Phylogenetic analysis of the genus <i>Corynebacterium</i> based on 16S rRNA gene sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):724-728 (1995)
X85965	aroP; dapE	Aromatic amino acid permease; ?	Wehrmann, A. et al. "Functional analysis of sequences adjacent to dapE of <i>Corynebacterium glutamicum</i> proline reveals the presence of aroP, which encodes the aromatic amino acid transporter," <i>J. Bacteriol.</i> , 177(20):5991-5993 (1995)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X86157	argB; argC; argD; argF; argJ	Acetylglutamate kinase; N-acetyl-gamma-glutamyl-phosphate reductase; acetylornithine aminotransferase; ornithine carbamoyltransferase; glutamate N-acetyltransferase	Sakanyan, V. et al. "Genes and enzymes of the acetyl cycle of arginine biosynthesis in <i>Corynebacterium glutamicum</i> : enzyme evolution in the early steps of the arginine pathway," <i>Microbiology</i> , 142:99-108 (1996)
X89084	pta; ackA	Phosphate acetyltransferase; acetate kinase	Reinscheid, D.J. et al. "Cloning, sequence analysis, expression and inactivation of the <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase and acetate kinase," <i>Microbiology</i> , 145:503-513 (1999)
X89850	attB	Attachment site	Le Martec, C. et al. "Genetic characterization of site-specific integration functions of phi AAV2 infecting "Arthrobacter aureus C70," <i>J. Bacteriol.</i> , 178(7):1996-2004 (1996)
X90356		Promoter fragment F1	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90357		Promoter fragment F2	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90358		Promoter fragment F10	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90359		Promoter fragment F13	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90360		Promoter fragment F22	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90361		Promoter fragment F34	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90362		Promoter fragment F37	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)



GenBank™ Accession No.	Gene Name	Gene Function	Reference
X90363		Promoter fragment F45	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90364		Promoter fragment F64	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90365		Promoter fragment F75	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90366		Promoter fragment PF101	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90367		Promoter fragment PF104	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90368		Promoter fragment PF109	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X93513	amt	Ammonium transport system	Siewe, R.M. et al. "Functional and genetic characterization of the (methyl) ammonium uptake carrier of <i>Corynebacterium glutamicum</i> ," <i>J. Biol. Chem.</i> , 271(10):5398-5403 (1996)
X93514	betP	Glycine betaine transport system	Peter, H. et al. "Isolation, characterization, and expression of the <i>Corynebacterium glutamicum</i> betP gene, encoding the transport system for the compatible solute glycine betaine," <i>J. Bacteriol.</i> , 178(17):5229-5234 (1996)
5649	orf4		Patek, M. et al. "Identification and transcriptional analysis of the dapB-ORF2-dapA-ORF4 operon of <i>Corynebacterium glutamicum</i> , encoding two enzymes involved in L-lysine synthesis," <i>Biotechnol. Lett.</i> , 19:1113-1117 (1997)
X96471	lysE; lysG	Lysine exporter protein; Lysine export regulator protein	Vrjlic, M. et al. "A new type of transporter with a new type of cellular function: L-lysine export from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 22(5):815-826 (1996)

11/16/2011 10:23:00

Table 2, Page 15

GenBank™ Accession No.	Gene Name	Gene Function	Reference
Y12537	proP	Proline/ectoine uptake system protein	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)
Y13221	glnA	Glutamine synthetase I	Jakoby, M. et al. "Isolation of Corynebacterium glutamicum glnA gene encoding glutamine synthetase I," <i>FEMS Microbiol. Lett.</i> , 154(1):81-88 (1997)
Y16642	lpd	Dihydrodipicolinate dehydrogenase	Moreau, S. et al. "Analysis of the integration functions of $\phi$ phi3041. An integrase module among corynephages," <i>Virology</i> , 255(1):150-159 (1999)
8059		Attachment site Corynephage 304L	Oguiza, J.A. et al. "A gene encoding arginyl-tRNA synthetase is located in the upstream region of the lysA gene in Brevibacterium lactofermentum: Regulation of argS-lysA cluster expression by arginine," <i>J. Bacteriol.</i> , 175(22):7356-7362 (1993)
Z21501	argS; lysA	Arginyl-tRNA synthetase; diaminiopimelate decarboxylase (partial)	Pisabarro, A. et al. "A cluster of three genes (dapA, orf2, and dapB) of Brevibacterium lactofermentum encodes dihydrodipicolinate reductase, and a third polypeptide of unknown function," <i>J. Bacteriol.</i> , 175(9):2743-2749 (1993)
Z21502	dapA; dapB	Dihydrodipicolinate synthase; dihydrodipicolinate reductase	Malumbres, M. et al. "Analysis and expression of the thrC gene of the encoded threonine synthase," <i>Appl. Environ. Microbiol.</i> , 60(7):2209-2219 (1994)
Z29563	thrC	Threonine synthase	Oguiza, J.A. et al. "Multiple sigma factor genes in Brevibacterium lactofermentum: Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z46753	16S rDNA	Gene for 16S ribosomal RNA	Oguiza, J.A. et al. "The galE gene encoding the UDP-galactose 4-epimerase of Brevibacterium lactofermentum is coupled transcriptionally to the dmhR gene," <i>Gene</i> , 177:103-107 (1996)
Z49822	sigA	SigA sigma factor	Oguiza, J.A. et al. "Multiple sigma factor genes in Brevibacterium lactofermentum: Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z49823	galE; dtxR	Catalytic activity UDP-galactose 4-epimerase; diphtheria toxin regulatory protein	Correia, A. et al. "Cloning and characterization of an IS-like element present in the genome of Brevibacterium lactofermentum ATCC 13869," <i>Gene</i> , 170(1):91-94 (1996)
Z49824	orf1; sigB	?, SigB sigma factor	
Z66534		Transposase	

A sequence for this gene was published in the indicated reference. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

00603024 063000

TABLE 3: Corynebacterium and Brevibacterium Strains Which May be Used in the Practice of the Invention

Genus	Species	ATCC	FERM	NRRL	CECT	NCIMB	CBS	NCTC	DSMZ
Brevibacterium	ammoniaenes	21054							
Brevibacterium	ammoniaenes	19350							
Brevibacterium	ammoniaenes	19351							
Brevibacterium	ammoniaenes	19352							
Brevibacterium	ammoniaenes	19353							
Brevibacterium	ammoniaenes	19354							
Brevibacterium	ammoniaenes	19355							
Brevibacterium	ammoniaenes	19356							
Brevibacterium	ammoniaenes	21055							
Brevibacterium	ammoniaenes	21077							
Brevibacterium	ammoniaenes	21553							
Brevibacterium	ammoniaenes	21580							
Brevibacterium	ammoniaenes	39101							
Brevibacterium	butanicum	21196							
Brevibacterium	divaricatum	21792	P928						
Brevibacterium	flavum	21474							
Brevibacterium	flavum	21129							
Brevibacterium	flavum	21518							
Brevibacterium	flavum			B11474					
Brevibacterium	flavum			B11472					
Brevibacterium	flavum	21127							
Brevibacterium	flavum	21128							
Brevibacterium	flavum	21427							
Brevibacterium	flavum	21475							
Brevibacterium	flavum	21517							
Brevibacterium	flavum	21528							
Brevibacterium	flavum	21529							

00000000-000000

Brevibacterium	flavum			B11477						
Brevibacterium	flavum			B11478						
Brevibacterium	flavum	21127								
Brevibacterium	flavum			B11474						
Brevibacterium	healii	15527								
Brevibacterium	ketoglutanicum	21004								
Brevibacterium	ketoglutanicum	21089								
Brevibacterium	ketosoreductum	21914								
Brevibacterium	lactofermentum				70					
Brevibacterium	lactofermentum				74					
Brevibacterium	lactofermentum				77					
Brevibacterium	lactofermentum	21798								
Brevibacterium	lactofermentum	21799								
Brevibacterium	lactofermentum	21800								
Brevibacterium	lactofermentum	21801								
Brevibacterium	lactofermentum			B11470						
Brevibacterium	lactofermentum			B11471						
Brevibacterium	lactofermentum	21086								
Brevibacterium	lactofermentum	21420								
Brevibacterium	lactofermentum	21086								
Brevibacterium	lactofermentum	31269								
Brevibacterium	linens	9174								
Brevibacterium	linens	19391								
Brevibacterium	linens	8377								
Brevibacterium	paraffinolyticum				11160					
Brevibacterium	spec.					717.73				
Brevibacterium	spec.					717.73				
Brevibacterium	spec.	14604								
Brevibacterium	spec.	21860								
Brevibacterium	spec.	21864								
Brevibacterium	spec.	21865								

00603034 - 06303030



Corynebacterium	glutamicum	21514																	
Corynebacterium	glutamicum	21516																	
Corynebacterium	glutamicum	21299																	
Corynebacterium	glutamicum	21300																	
Corynebacterium	glutamicum	39684																	
Corynebacterium	glutamicum	21488																	
Corynebacterium	glutamicum	21649																	
Corynebacterium	glutamicum	21650																	
Corynebacterium	glutamicum	19223																	
Corynebacterium	glutamicum	13869																	
Corynebacterium	glutamicum	21157																	
Corynebacterium	glutamicum	21158																	
Corynebacterium	glutamicum	21159																	
Corynebacterium	glutamicum	21355																	
Corynebacterium	glutamicum	31808																	
Corynebacterium	glutamicum	21674																	
Corynebacterium	glutamicum	21562																	
Corynebacterium	glutamicum	21563																	
Corynebacterium	glutamicum	21564																	
Corynebacterium	glutamicum	21565																	
Corynebacterium	glutamicum	21566																	
Corynebacterium	glutamicum	21567																	
Corynebacterium	glutamicum	21568																	
Corynebacterium	glutamicum	21569																	
Corynebacterium	glutamicum	21570																	
Corynebacterium	glutamicum	21571																	
Corynebacterium	glutamicum	21572																	
Corynebacterium	glutamicum	21573																	
Corynebacterium	glutamicum	21579																	
Corynebacterium	glutamicum	19049																	
Corynebacterium	glutamicum	19050																	





FERM: Fermentation Research Institute, Chiba, Japan

CECT: Coleccion Espanola de Cultivos Tipo, Valencia, Spain

NCIMB: National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK

CBS: Centraalbureau voor Schimmelmcultures, Baarn, NL

NCTC: National Collection of Type Cultures, London, UK

DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany

For reference see Sugawara, H. et al. (1993) World directory of collections of cultures of microorganisms: Bacteria, fungi and yeasts (4<sup>th</sup> edn), World federation for culture collections world data center on microorganisms, Saimata, Japan.

TABLE 4: ALIGNMENT RESULTS

ID # (NT)	length	Genbank Hit	Length	Accession	Name of Genbank Hit	Source of Genbank Hit	% homology (GAP)	Date of Deposit
rx000001	1251	GB_BA1:SRMSIK GB_BA1:SLU12007	2384 1602	Y08921 U12007	S. reticul gene encoding Msk protein and ofrl. Streptomyces lividans 1326 ATP binding protein Msk (msk) gene, complete cds.	Streptomyces reticul Streptomyces lividans	63,746 62,951	21-MAR-1997 30-MAR-1996
rx000002	807	GB_BA1:MTCV16B7 GB_EST22:AU020788	43430 558	Z81331 AU020788	Mycobacterium tuberculosis H37Rv complete genome; segment 123/162. AU020788 Mouse eight-cell stage embryo cDNA Mus musculus cDNA clone J0538B03 3', mRNA sequence.	Mycobacterium tuberculosis Mycobacterium tuberculosis Mus musculus	41,425 37,913 38,757	17-Jun-98 18-Jun-98 19-OCT-1998
rx000089	1122	GB_PR3:AC004160 GB_EST27:AA61009	143751 570	AC004160 AA61009	Homo sapiens BAC clone GS164B05 from 7p21-p22, complete sequence. sa77g07.y1 Gm-c1004 Glycine max cDNA clone GENOME SYSTEMS CLONE ID: Gm-c1004-5365 5' similar to TR:004014 004014 RIBOSOMAL PROTEIN S6 RPS6-1., mRNA sequence.	Homo sapiens Glycine max	35,687 37,833	20-Feb-98 01-DEC-1999
		GB_EST32:AT736780	474	AT736780	sb33d08.y1 Gm-c1012 Glycine max cDNA clone GENOME SYSTEMS CLONE ID: Gm-c1012-232 5' similar to TR:004014 004014 RIBOSOMAL PROTEIN S6 RPS6-1., mRNA sequence.	Glycine max	37,367	06-DEC-1999
		GB_EST30:AI637616	280	AI637616	tt10c03.x1 NCL_CGAP_G06 Homo sapiens cDNA clone IMAGE:2240356 3', mRNA sequence.	Homo sapiens	37,455	27-Apr-99
rx000090	1242	GB_PL1:SCYOR023C	1989	Z74931	S.cerevisiae chromosome XV reading frame ORF YOR023c.	Saccharomyces cerevisiae	36,078	11-Aug-97
		GB_GSS15:AAQ659370	487	AAQ659370	Sheared DNA-5C3, TR Sheared DNA Trypanosoma brucei genomic clone Sheared DNA-5C3, genomic survey sequence.	Trypanosoma brucei	44,920	23-Jun-99
rx000099	1296	GB_PL1:MZEHSZEIN GB_HTG1:HSDA14C6	2123 155908	L29505 AL049732	Zea mays high sulfur zein gene, complete cds. Homo sapiens chromosome X clone RP6-14C6, *** SEQUENCING IN PROGRESS *** in unordered pieces.	Zea mays Homo sapiens	37,245 35,984	24-MAR-1994 23-Nov-99
		GB_HTG1:HSDA14C6	155908	AL049732	Homo sapiens chromosome X clone RP6-14C6, *** SEQUENCING IN PROGRESS *** in unordered pieces.	Homo sapiens	35,984	23-Nov-99
		GB_PL2:ATF22113	93760	AL035539	Arabidopsis thaliana DNA chromosome 4, BAC clone F22113 (ESSA project).	Arabidopsis thaliana	35,161	27-Aug-99
rx000123	1242	GB_PL1:OS4CL GB_BA1:AB020531	5225 6445	X52623 AB020531	Rice 4-CL gene for 4-coumarate-CoA ligase (EC 6.2.1.12). Escherichia coli plasmid pTZ3721 gene cluster containing the mphB gene for macrolide 2'-phosphotransferase II, complete cds.	Oryza sativa Escherichia coli	39,330 36,923	7-Apr-93 20-Feb-99
rx000160	696	GB_PL1:OS4CL GB_EST11:AA270696	5225 178	X52623 AA270696	Rice 4-CL gene for 4-coumarate-CoA ligase (EC 6.2.1.12). va46g09.t1 Soares mouse 3NME12 5 Mus musculus cDNA clone IMAGE:734464 5' similar to gb:M17886 60S ACIDIC RIBOSOMAL PROTEIN P1 (HUMAN); gb:U29402 Mus musculus acidic ribosomal phosphoprotein P1 mRNA, complete (MOUSE), mRNA sequence.	Oryza sativa Mus musculus	39,118 46,067	7-Apr-93 26-MAR-1997
		GB_HTG3:AC010829	149101	AC010829	Homo sapiens clone 6_J_21, LOW-PASS SEQUENCE SAMPLING.	Homo sapiens	36,880	23-Sep-99
		GB_HTG3:AC010829	149101	AC010829	Homo sapiens clone 6_J_21, LOW-PASS SEQUENCE SAMPLING.	Homo sapiens	36,880	23-Sep-99

00503024-0523000

Variable	Mean	SD	Min	Max
Age	34.5	10.2	18	65
Gender	50.0	0.0	0	1
Marital status	65.0	0.0	0	1
Education	12.5	1.5	9	16
Income	35.0	15.0	10	70
Health status	75.0	10.0	60	90
Stress level	45.0	15.0	30	60
Life satisfaction	60.0	10.0	40	80
Work satisfaction	55.0	12.0	35	75
Family satisfaction	65.0	11.0	45	85
Community satisfaction	50.0	13.0	30	70
Overall satisfaction	58.0	14.0	38	78

TABLE 4: ALIGNMENT RESULTS

rx00378	2733	GB_BA2:ALW243431	26953	AJ243431	Acinetobacter lwofii wzc, wzb, wza, weeA, weeB, wceC, wzx, wzy, weeD, weeE, weeF, weeG, weeH, weel, weej, week, galU, ugd, pgi, galE, pgm (partial) and mip (partial) genes (emmisan biosynthetic gene cluster), strain RAG-1.	Acinetobacter lwofii	36,717	01-OCT-1999
		GB_BA2:ALW243431	26953	AJ243431	Acinetobacter lwofii wzc, wzb, wza, weeA, weeB, wceC, wzx, wzy, weeD, weeE, weeF, weeG, weeH, weel, weej, week, galU, ugd, pgi, galE, pgm (partial) and mip (partial) genes (emmisan biosynthetic gene cluster), strain RAG-1.	Acinetobacter lwofii	36,394	01-OCT-1999
rx00412	1203	GB_RO:MMCOL3A1	43601	X52046	M.musculus COL3A1 gene for collagen alpha-1.	Mus musculus	35,159	8-Nov-94
		GB_BA1:ECU70214	123171	U70214	Escherichia coli chromosome minutes 4-6.	Escherichia coli	39,914	21-Sep-96
		GB_BA1:ECOTSF	91430	D83536	Escherichia coli genomic DNA. (4.1 - 6.1 min).	Escherichia coli	39,828	28-MAY-1999
		GB_HTG3:AC011366	177590	AC011366	Homo sapiens chromosome 5 clone CIT-HSPC_568L21, ***	Homo sapiens	46,212	06-OCT-1999
rx00413	1020	GB_PR3:AC005209	184130	AC005209	SEQUENCING IN PROGRESS *** 82 unordered pieces.			
		GB_PR3:AC005209	184130	AC005209	Homo sapiens chromosome 17, clone hRPK.628_O_18, complete sequence.	Homo sapiens	34,028	24-Jul-98
		GB_PR3:HUMILBR	13089	M99412	Human interleukin-8 receptor (IL8RB) gene, complete cds.	Homo sapiens	37,934	22-Apr-98
		GB_PR4:AC006974	90241	AC006974	Homo sapiens PAC clone DJ0956B11 from 7q33-q36, complete sequence.	Homo sapiens	37,948	29-Jul-99
rx00431	912	GB_BA1:MSGY126	37164	AD000012	Mycobacterium tuberculosis sequence from clone y126.	Mycobacterium tuberculosis	66,776	10-DEC-1996
		GB_BA1:MTY13D12	37085	Z80343	Mycobacterium tuberculosis H37Rv complete genome: segment 156/162.	Mycobacterium tuberculosis	66,776	17-Jun-98
rx00444	960	GB_BA1:MSGB971CS	37566	L78821	Mycobacterium leprae cosmid B971 DNA sequence.	Mycobacterium leprae	39,429	15-Jun-96
		GB_PR4:AC007564	194058	AC007564	Homo sapiens 12q22 BAC RPC111-513P18 (Roswell Park Cancer Institute Human BAC Library) complete sequence.	Homo sapiens	35,220	3-Jul-99
		GB_HTG4:AC007553	271496	AC007553	Homo sapiens chromosome 12q22-102.7-103.4 clone RPC111-557K11, ***	Homo sapiens	35,408	21-OCT-1999
		GB_HTG4:AC007553	271496	AC007553	SEQUENCING IN PROGRESS *** 70 unordered pieces.			
		GB_HTG4:AC007553	271496	AC007553	Homo sapiens chromosome 12q22-102.7-103.4 clone RPC111-557K11, ***	Homo sapiens	35,408	21-OCT-1999
rx00445	1035	GB_HTG3:AC011455_0244238	AC011455		SEQUENCING IN PROGRESS *** 70 unordered pieces.			
		GB_HTG3:AC011455_0244238	AC011455		Homo sapiens chromosome 19 clone CIT-HSPC_360G5, ***	Homo sapiens	35,455	19-Dec-99
		GB_HTG3:AC011455_0244238	AC011455		SEQUENCING IN PROGRESS *** 287 unordered pieces.			
		GB_HTG3:AC011455_0244238	AC011455		Homo sapiens chromosome 19 clone CIT-HSPC_360G5, ***	Homo sapiens	35,455	19-Dec-99
		GB_HTG3:AC011455_0244238	AC011455		SEQUENCING IN PROGRESS *** 287 unordered pieces.			
		GB_HTG3:AC011455_0244238	AC011455		Homo sapiens chromosome 19 clone CIT-HSPC_360G5, ***	Homo sapiens	41,511	19-Dec-99
rx00466					SEQUENCING IN PROGRESS *** 287 unordered pieces.			
rx00482	771	GB_PR4:AF119709	43566	AF119709	Homo sapiens chromosome 8q24 BAC clone H103, complete sequence.	Homo sapiens	36,724	28-Feb-99
		GB_RO:AC006960	158414	AC006960	Mus musculus chromosome 17 BAC c1b20n22 from the MHC region, complete sequence.	Mus musculus	39,836	01-DEC-1998
		GB_RO:MUSMHH2M4X394	L14278		Mouse MHC class I H2-M4 gene, exons 1-5.	Mus musculus	32,713	11-Aug-93

00603034 : 063400

**TABLE 4: ALIGNMENT RESULTS**

rx00523	1149	GB_BA2:AF176902	3032	AF176902	Corynebacterium diptheriae IRP1B (irp1B), IRP1C (irp1C), and IRP1D (irp1D) genes, complete cds.	Corynebacterium diptheriae	58,781	5-Sep-99
		GB_HTG3:AC002489	91638	AC002489	Mus musculus chromosome X clone 592 map X, *** SEQUENCING IN PROGRESS ***, 8 unordered pieces.	Mus musculus	37,819	3-Aug-99
		GB_HTG3:AC002489	91638	AC002489	Mus musculus chromosome X clone 592 map X, *** SEQUENCING IN PROGRESS ***, 8 unordered pieces.	Mus musculus	37,819	3-Aug-99
rx00525	1386	GB_BA1:D90917	154619	D90917	Synechocystis sp. PCC6803 complete genome, 27/27, 3418862-3573470.	Synechocystis sp.	46,966	7-Feb-99
		GB_PL1:AOF132610	477	AJ132610	Asparagus officinalis mRNA for intracellular pathogenesis-related protein, isoform 4.	Asparagus officinalis	38,819	1-Feb-99
		GB_PAT:A26571	737	A26571	A.officinalis AoPR1 gene.	Asparagus officinalis	37,620	28-Sep-95
rx00596	576	GB_PR3:AC004659	129577	AC004659	Homo sapiens chromosome 19, CIT-HSP-87m17 BAC clone, complete sequence.	Homo sapiens	34,321	02-MAY-1998
		GB_PR3:AC004659	129577	AC004659	Homo sapiens chromosome 19, CIT-HSP-87m17 BAC clone, complete sequence.	Homo sapiens	35,739	02-MAY-1998
		GB_PR1:HUMCBP2	2047	D83174	Human mRNA for collagen binding protein 2, complete cds.	Homo sapiens	40,404	6-Feb-99
rx00634	1506	GB_BA1:BRLBIOAD	2272	D14083	Brevibacterium flavum genes for 7,8-diaminopelargonic acid aminotransferase and dethiobiotin synthetase, complete cds.	Corynebacterium glutamicum	39,111	3-Feb-99
		GB_PAT:E08643	285	E08643	Base sequence having the promoter function in Corynebacterium microorganisms.	Corynebacterium glutamicum	39,111	29-Sep-97
		GB_HTG2:AC006174	203407	AC006174	Homo sapiens chromosome 10 clone CIT987SK-1057L21 map 10q25, *** SEQUENCING IN PROGRESS ***, 6 unordered pieces.	Homo sapiens	37,517	09-DEC-1998
rx00665	601	GB_BA1:SC130A	35033	AL096811	Streptomyces coelicolor cosmid 130A.	Streptomyces coelicolor A3(2)	38,095	22-Jul-99
		GB_PR3:AC002366	259202	AC002366	Human Xp22 BAC CT-28515 (from CalTech/Research Genetics), PAC RPC1-27C22 (from Roswell Park Cancer Center), and Cosmid U35B5 (from Lawrence Livermore), complete sequence.	Homo sapiens	33,045	11-Jun-98
		GB_PR3:AC002366	259202	AC002366	Human Xp22 BAC CT-28515 (from CalTech/Research Genetics), PAC RPC1-27C22 (from Roswell Park Cancer Center), and Cosmid U35B5 (from Lawrence Livermore), complete sequence.	Homo sapiens	35,214	11-Jun-98
rx00702	1830	GB_BA1:PLNRTABC	6449	Z19598	P.lamiosum nrtA-Pil, nrtB-Pil and nrtC-Pil genes.	Phormidium lamiosum	40,550	7-Feb-96
		GB_GSS10:AQ256518	704	AQ256518	nbxb0016M14r CUGI Rice BAC Library Oryza sativa genomic clone nbxb0016M14r, genomic survey sequence.	Oryza sativa	41,477	23-OCT-1998
		GB_BA1:AAC243194	1720	AJ243194	Allicyclobacillus acidocaldarius kdpA gene.	Allicyclobacillus acidocaldarius	39,740	21-Jun-99
rx00728	892	GB_EST21:AA974252	426	AA974252	oq14A01.s1 NCI_CGAP GC4 Homo sapiens cDNA clone IMAGE:1586280 3' similar to SW/LIPA_ECOL P25845 LIPOIC ACID SYNTHETASE ;contains MER22.12 MER22 repetitive element ;, mRNA sequence.	Homo sapiens	42,236	7-Jul-98
		GB_HTG2:AC004060	124000	AC004060	Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, 10 unordered pieces.	Homo sapiens	38,106	21-Jul-98
		GB_HTG2:AC004060	124000	AC004060	Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, 10 unordered pieces.	Homo sapiens	38,106	21-Jul-98

06503024 062300

**TABLE 4: ALIGNMENT RESULTS**

rx00732	1670	GB_BA2:AE000241	10160	AE000241	Escherichia coli K-12 MG1655 section 131 of 400 of the complete genome.	Escherichia coli	40,024	12-Nov-98
		GB_HTG3:AC010073	121859	AC010073	Homo sapiens chromosome 15 clone BAC 16E3 map 15q25, LOW-PASS SEQUENCE SAMPLING.	Homo sapiens	39,001	11-Sep-99
		GB_BA1:D90783	15399	D90783	E.coli genomic DNA, Kohara clone #272(32.4-32.7 min.).	Escherichia coli	40,024	29-MAY-1997
rx00759	1047	GB_BA1:MTV025	121125	AL022121	Mycobacterium tuberculosis H37Rv complete genome; segment 155/162.	Mycobacterium tuberculosis	39,960	24-Jun-99
		GB_PL1:BPNI1R1	2472	X60093	B.pendula mRNA for nitrite reductase.	Betula pendula	38,106	19-MAR-1992
		GB_BA1:MTV025	121125	AL022121	Mycobacterium tuberculosis H37Rv complete genome; segment 155/162.	Mycobacterium tuberculosis	41,618	24-Jun-99
rx00760	1155	GB_BA2:AF092918	20758	AF092918	Pseudomonas alcaligenes outer membrane Xcp-secretion system gene cluster.	Pseudomonas alcaligenes	40,450	06-DEC-1998
		GB_BA1:SC17	34893	AL096743	Streptomyces coelicolor cosmid 17.	Streptomyces coelicolor	40,352	1-Jul-99
rx00774	777	GB_BA1:D90763	18199	D90763	E.coli genomic DNA, Kohara clone #252(28.1-28.4 min.).	Escherichia coli	38,747	29-MAY-1997
		GB_EST8:AA020814	419	AA020814	ze63h10.s1 Soares retina N2b4HR Homo sapiens cDNA clone IMAGE:363715 3' similar to PIR-A35715 A35715 fodrin alpha chain - human ;, mRNA sequence.	Homo sapiens	37,500	30-Jan-97
		GB_PL2:ATAC004521	104797	AC004521	Arabidopsis thaliana chromosome II BAC F411 genomic sequence.	Arabidopsis thaliana	36,411	12-MAY-1998
		GB_PL2:ATAC004521	104797	AC004521	Arabidopsis thaliana chromosome II BAC F411 genomic sequence.	Arabidopsis thaliana	38,589	12-MAY-1998
rx00775	894	GB_BA1:MTV043	68848	AL022004	Mycobacterium tuberculosis H37Rv complete genome; segment 40/162.	Mycobacterium tuberculosis	66,107	24-Jun-99
		GB_BA2:AF045938	777	AF045938	Mycobacterium smegmatis putative ABC transporter nucleotide binding subunit (mtp1) gene, complete cds.	Mycobacterium smegmatis	73,454	02-MAY-1998
		GB_BA1:MLU15182	40123	U15182	Mycobacterium leprae cosmid B2266.	Mycobacterium leprae	63,494	09-MAR-1995
rx00776	1044	GB_PR3:HS453C12	147620	AL021578	Human DNA sequence from clone 453C12 on chromosome 20q12-13.12, complete sequence.	Homo sapiens	35,833	23-Nov-99
		GB_PR3:AC004877	128361	AC004877	Homo sapiens PAC clone DJ0751H13 from 7q35-qter, complete sequence.	Homo sapiens	38,754	19-Sep-98
		GB_PR3:HS30012	63796	AL035660	Human DNA sequence from clone 30012 on chromosome 20q12-13.12, complete sequence.	Homo sapiens	32,233	23-Nov-99
rx00777	1188	GB_BA1:ASAJ187	6213	AJ000187	Arthrobacter sp. catA gene.	Arthrobacter sp.	49,694	5-Jul-99
		GB_IN1:CELT20D4	42052	U80029	Caenorhabditis elegans cosmid T20D4.	Caenorhabditis elegans	36,457	04-DEC-1996
		GB_GSS4:AQ693388	531	AQ693388	HS_5458_A2 D10_77A RPCL-11 Human Male BAC Library/Homo sapiens genomic clone Plate=1034 Col=20 Row=G, genomic survey sequence.	Homo sapiens	38,123	6-Jul-99
rx00828	576	GB_GSS1:CNS00ZMZ	796	AL097877	Drosophila melanogaster genome survey sequence SP6 end of BAC BACND2F13 of DrosBAC library from Drosophila melanogaster (fruit fly), genomic survey sequence.	Drosophila melanogaster	39,286	26-Jul-99
		GB_BA1:PSEBPH	4169	D16407	Pseudomonas sp. bphE, bphG, bphF and ORF4 genes.	Pseudomonas sp.	36,364	4-Feb-99
		GB_GSS9:AQ156606	668	AQ156606	nbxb0008K19r CUGI Rice BAC Library Oryza sativa genomic clone nbxb0008K19r, genomic survey sequence.	Oryza sativa	36,364	12-Sep-98

06603024-063300

TABLE 4: ALIGNMENT RESULTS

rx00832	1173	GB_PR4:AC006504	210137	AC006504	Homo sapiens chromosome 19, BAC 326584 (CIT-B-459F4), complete sequence.	Homo sapiens	40,545	4-Feb-99
		GB_GSS12:AQ417775	642	AQ417775	RPC1-11-197B9, TV RPC1-11 Homo sapiens genomic clone RPC1-11-197B9, genomic survey sequence.	Homo sapiens	44,286	23-MAR-1999
		GB_PR4:AC006504	210137	AC006504	Homo sapiens chromosome 19, BAC 326584 (CIT-B-459F4), complete sequence.	Homo sapiens	35,886	4-Feb-99
rx00934	1206	GB_BA1:MLCL581	36225	Z96801	Mycobacterium leprae cosmid L581.	Mycobacterium leprae	38,243	24-Jun-97
		GB_BA1:MTCY1A10	25949	Z95387	Mycobacterium tuberculosis H37Rv complete genome; segment 11/17/162.	Mycobacterium tuberculosis	38,350	17-Jun-98
		GB_PR3:HS434O14	135928	AL022398	Homo sapiens DNA sequence from PAC 434O14 on chromosome 1q32.3-41. Contains the HSD11B1 gene for Hydroxysteroid (11-beta) Dehydrogenase 1, the ADORA2BP adenosine A2b receptor LIKE pseudogene, the IRF6 gene for Interferon Regulatory Factor 6 and two novel genes. Contains ESTs and GSSs, complete sequence.	Homo sapiens	36,788	23-Nov-99
rx00939	1308	GB_BA1:MTCY251	38380	Z74410	Mycobacterium tuberculosis H37Rv complete genome; segment 5/162.	Mycobacterium tuberculosis	49,462	17-Jun-98
		GB_PAT1:P6656	3250	I26656	Sequence 1 from patent US 5559011.	Unknown.	49,462	07-OCT-1996
		GB_BA2:SCJ1	36925	AL109962	Streptomyces coelicolor cosmid J1.	Streptomyces coelicolor A3(2)	49,228	24-Sep-99
rx00942	327	GB_JN1:CELT19D2	28406	U42846	Caenorhabditis elegans cosmid T19D2.	Caenorhabditis elegans	43,910	19-DEC-1995
		GB_PR4:AC004905	134350	AC004905	Homo sapiens PAC clone DU0845121 from 7q11.21-q11.23, complete sequence.	Homo sapiens	35,505	12-Jan-99
rx00950	1029	GB_JN1:CELF18C5	29095	U29097	Caenorhabditis elegans cosmid F18C5.	Caenorhabditis elegans	37,107	15-Jun-95
		GB_BA1:SLTNRB	2849	X73633	S.lorigisporoflavus TrnB gene.	Streptomyces lorigisporoflavus	52,255	9-Aug-94
		GB_BA1:MTCI364	29540	Z93777	Mycobacterium tuberculosis H37Rv complete genome; segment 52/162.	Mycobacterium tuberculosis	38,872	17-Jun-98
		GB_BA1:MSGY367	35336	AD000008	Mycobacterium tuberculosis sequence from clone y367.	Mycobacterium tuberculosis	39,921	03-DEC-1996
rx00960	1058	GB_PL2:ATAC009325	105543	AC009325	Arabidopsis thaliana chromosome III BAC F4P13 genomic sequence, complete sequence.	Arabidopsis thaliana	36,074	08-OCT-1999
		GB_BA2:U59485	29078	U59485	Agrobacterium tumefaciens AtrC (atrC) gene, partial cds; AtrB (atrB), AtrA (atrA), AttA1 (attA1), AttA2 (attA2), AttB (attB), AttC (attC), AttD (attD), AttE (attE), and AttF (attF) genes, complete cds; AttG (attG) gene, alternative splice products, complete cds; AttH (attH), AttI (attI), AttJ (attJ), AttK (attK), AttL (attL), AttM (attM), AttO (attO), AttP (attP), AttR (attR), AttS (attS), AttT (attT), AttU (attU), AttV (attV), AttW (attW), AttX (attX), AttY (attY), AttZ (attZ), AtsA (atsA), AtsB (atsB), AtsC (atsC), and AtsD (atsD) genes, complete cds; and AtsE (atsE) gene, partial cds.	Agrobacterium tumefaciens	39,884	16-Jul-99
		GB_PL2:ATAC009325	105543	AC009325	Arabidopsis thaliana chromosome III BAC F4P13 genomic sequence, complete sequence.	Arabidopsis thaliana	36,162	08-OCT-1999
rx00980	1917	GB_BA1:MTCY10D7	39800	Z79700	Mycobacterium tuberculosis H37Rv complete genome; segment 44/162.	Mycobacterium tuberculosis	48,176	17-Jun-98

00503024-052300

**TABLE 4: ALIGNMENT RESULTS**

		GB_GSS10:AQ255373	639	AQ255373	mgxb0012D24r CUGI Rice Blast BAC Library Magnaporthe grisea genomic clone mgxb0012D24r, genomic survey sequence.	38,624	23-OCT-1998
		GB_EST26:AU004809	728	AU004809	Bombyx mori p50(Daizo) Bombyx mori cDNA clone ws20873, mRNA sequence.	38,223	19-Jan-99
rx001000							
rx001002	927	GB_BA2:AE001197	10039	AE001197	Treponema pallidum section 13 of 87 of the complete genome.	37,161	16-Jul-98
		GB_PL1:HVPGLYH	3790	Y10089	H. vulgare mRNA for novel P-glycoprotein homologue.	42,239	24-OCT-1997
		GB_JN1:AB003329	4328	AB003329	Leishmania amazonensis LamDR1 multidrug resistance gene, complete cds.	40,176	24-MAR-1999
rx001003	927	GB_HTG2:HSJ168B21	67973	AL118518	Homo sapiens chromosome 6 clone RP1-168B21 map q26-27, *** SEQUENCING IN PROGRESS *** in unordered pieces.	35,159	03-DEC-1999
		GB_HTG2:HSJ168B21	67973	AL118518	Homo sapiens chromosome 6 clone RP1-168B21 map q26-27, *** SEQUENCING IN PROGRESS *** in unordered pieces.	35,159	03-DEC-1999
		GB_HTG2:HSJ168B21	67973	AL118518	Homo sapiens chromosome 6 clone RP1-168B21 map q26-27, *** SEQUENCING IN PROGRESS *** in unordered pieces.	39,956	03-DEC-1999
rx001006	958	GB_JN2:S74163	2630	S74163	Drosophila sp. T-related protein (Trg) mRNA, complete cds.	37,131	06-OCT-1999
		GB_PR4:AF130343	292721	AF130343	Homo sapiens chromosome 8 clone PAC 87.2 map 8q24.1, complete sequence.	34,398	9-Jul-99
		GB_HTG3:AC009415	186991	AC009415	Homo sapiens clone NH0576H09, *** SEQUENCING IN PROGRESS *** 5 unordered pieces.	36,325	21-Aug-99
rx001012	1764	GB_BA1:SYOATPBP	2883	D14438	Synechococcus elongatus genes for ATP-binding protein and Mn-stabilizing protein.	50,346	3-Feb-99
		GB_BA1:BSU20909	6404	U20909	Bacillus subtilis permease system App operon AppD (appD), AppF(appF), AppA (appA), AppB (appB), and AppC (appC) genes, complete cds.	50,376	23-Feb-95
		GB_BA2:ECOPOTABCD385		M64519	E. coli transport protein (potA, potB, potC and potD) genes, complete cds.	42,881	17-Jun-96
rx001013	818	GB_JN2:AC005930	41284	AC005930	Leishmania major chromosome 3 clone L712 strain Friedlin, complete sequence.	40,444	13-Nov-99
		GB_PR2:HS1110P6	40033	AL049175	Human DNA sequence from clone 1110P6 on chromosome Xq21.1-22.3. Contains a putative CpG island, complete sequence.	36,981	23-Nov-99
		GB_JN2:AC005930	41284	AC005930	Leishmania major chromosome 3 clone L712 strain Friedlin, complete sequence.	44,121	13-Nov-99
rx001070	1509	GB_BA2:U32795	10038	U32795	Haemophilus influenzae Rd section 110 of 163 of the complete genome.	44,668	29-MAY-1998
		GB_PR4:AC004985	159507	AC004985	Homo sapiens clone DJ1165K10, complete sequence.	37,508	7-Aug-99
		GB_PR3:AC005244	127506	AC005244	Homo sapiens chromosome 17, clone hRPK471_L_13, complete sequence.	33,176	7-Aug-98
rx001094	736	GB_BA1:CORPYKI	2795	L27126	Corynebacterium pyruvate kinase gene, complete cds.	99,558	07-DEC-1994
		GB_BA1:SC4G6	36917	AL096884	Streptomyces coelicolor cosmid 4G6.	37,569	23-Jul-99
						A3(2)	

00603024-062300



TABLE 4: ALIGNMENT RESULTS

rxa01141	948	GB_HTG1:CNS01DS1	216986	AL121612	Homo sapiens chromosome 14 clone R-179A9, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Homo sapiens	38,577	15-OCT-1999
		GB_HTG2:HSJ395C13	150336	AL117344	Homo sapiens chromosome 6 clone RP3-395C13 map q25.2-26, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Homo sapiens	36,538	03-DEC-1999
		GB_HTG2:HSJ395C13	150336	AL117344	Homo sapiens chromosome 6 clone RP3-395C13 map q25.2-26, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Homo sapiens	36,538	03-DEC-1999
		GB_HTG2:HSJ395C13	150336	AL117344	Homo sapiens chromosome 6 clone RP3-395C13 map q25.2-26, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Homo sapiens	37,908	03-DEC-1999
rxa01142	621	GB_BA1:CORAL	4705	L09232	Corynebacterium glutamicum acetylhydroxy acid synthase (livB) and (livN) genes, and acetylhydroxy acid isomerase (livC) gene, complete cds.	Corynebacterium glutamicum	35,897	23-Feb-95
		GB_BA1:SCH35	45396	AL078610	Streptomyces coelicolor cosmid H35.	Streptomyces coelicolor	52,295	4-Jun-99
		GB_BA2:AFACHRRRA	7390	J05278	Ralstonia eutropha ChrB (chrB), ChrA (chrA), ChrC (chrC), ChrD (chrD), YvbB (yvbB), pirin, and heat shock protein sigma-32 (RP32) genes, complete cds.	Ralstonia eutropha	54,589	26-MAR-1999
rxa01164	1758	GB_GSS14:AQ55104	609	AQ55104	RPC1-11-415H1, TJ RPC1-11 Homo sapiens genomic clone RPC1-11-415H1, genomic survey sequence.	Homo sapiens	40,000	28-MAY-1999
		GB_BA2:AE000309	13453	AE000309	Escherichia coli K-12 MG1655 section 199 of 400 of the complete genome.	Escherichia coli	39,261	12-Nov-98
		GB_GSS14:AQ548213	668	AQ548213	RPC1-11-415H4, TV RPC1-11 Homo sapiens genomic clone RPC1-11-415H4, genomic survey sequence.	Homo sapiens	41,176	28-MAY-1999
rxa01168	933	GB_BA1:MTV018	53450	AL021899	Mycobacterium tuberculosis H37Rv complete genome; segment 90/162.	Mycobacterium tuberculosis	38,033	18-Jun-98
		GB_PL2:ATAC003033	84254	AC003033	Arabidopsis thaliana chromosome II BAC T21L14 genomic sequence, complete sequence.	Arabidopsis thaliana	37,486	19-DEC-1997
		GB_PL2:ATAC003033	84254	AC003033	Arabidopsis thaliana chromosome II BAC T21L14 genomic sequence, complete sequence.	Arabidopsis thaliana	38,142	19-DEC-1997
rxa01185	667	GB_BA2:AF013987	3150	AF013987	Vibrio cholerae strain 0395 putative ABC transporter ATP-binding protein, sigma54 (rpoN), putative sigma54 modulation protein and nitrogen regulatory IIA protein (pIsN) genes, complete cds.	Vibrio cholerae	44,128	21-MAY-1998
		GB_BA1:SASTPSMP	1848	Z30588	S. aureus (RN4220) genes for potential ABC transporter and potential membrane spanning protein.	Staphylococcus aureus	43,402	25-MAY-1995
		GB_PR3:HS357116	134506	AL021921	Homo sapiens DNA sequence from PAC 357116 on chromosome 1p36.13. Contains GSSs, genomic marker D1S449 and a CA repeat polymorphism, complete sequence.	Homo sapiens	38,957	23-Nov-99
rxa01188	1227	GB_PR3:HSN21F1	39212	Z94162	Human DNA sequence from cosmid N21F1 on chromosome 22 Contains exon trap and STS, complete sequence.	Homo sapiens	37,277	23-Nov-99
		GB_EST38:AW066174	465	AW066174	687007C06.y1 687 - Early embryo from Delaware Zee may's cDNA, mRNA Zee may's sequence.	Zee may's	42,439	12-OCT-1999
		GB_GSS4:AQ719542	493	AQ719542	HS_5529_B2_A02_SP0E RPC1-11 Human Male BAC Library Homo sapiens genomic clone Plate=1105 Col=4 Row=B, genomic survey sequence.	Homo sapiens	39,837	14-Jul-99

00603034-069900

TABLE 4: ALIGNMENT RESULTS

ra01247	357	GB_BA2.AF127374	63734	AF127374	Streptomyces lavendulae LinA homolog, cytochrome P450 hydroxylase ORF4, cytochrome P450 hydroxylase ORF3, MitT (mitT), Mts (mts), MitR (mitR), MitQ (mitQ), MitP (mitP), MitO (mitO), MitN (mitN), MitM (mitM), MitL (mitL), MitK (mitK), MitJ (mitJ), MitI (mitI), MitH (mitH), MitG (mitG), MitF (mitF), MitE (mitE), MitD (mitD), MitC (mitC), MitB (mitB), MitA (mitA), Mmca (mmca), Mmcb (mmcb), Mmcc (mmcc), Mmcd (mmcd), Mmce (mmce), Mmcf (mmcf), Mmcg (mmcg), Mmch (mmch), Mmcl (mmcl), Mmck (mmck), Mmcl (mmcl), Mmcm (mmcm), Mmcn (mmcn), Mmco (mmco), Mmd (mmd), Mmcp (mmcp), Mmcq (mmcq), Mmcr (mmcr), Mmcs (mmcs), Mmct (mmct), Mmcu (mmcu), Mmcv (mmcv), Mct (mct), Mmcv (mmcv), Mmcx (mmcx), and Mmcy (mmcy) genes, complete cds, and unknown genes.	Streptomyces lavendulae	38,592	27-MAY-1999
ra01285	749	GB_PR4.AC006039	176257	AC006039	Homo sapiens clone NH0319F03, complete sequence.	Homo sapiens	30,899	05-MAY-1999
		GB_BA1.SCI51	40745	AL109848	Streptomyces coelicolor cosmid I51.	Streptomyces coelicolor A3(2)	38,627	16-Aug-99
		GB_BA2.SCF34	38995	AL109974	Streptomyces coelicolor cosmid F34.	Streptomyces coelicolor A3(2)	38,586	24-Sep-99
		GB_BA2.MSU10425	4261	U10425	Mycobacterium smegmatis ferric exochelin uptake proteins FxuB (fxuB), FxuA (fxuA) genes, complete cds, FxuC (fxuC) gene, partial cds, and ferric exochelin biosynthesis protein FxuD (fxuD) gene, complete cds.	Mycobacterium smegmatis	61,230	07-DEC-1994
ra01289	1167	GB_BA1.SCI51	40745	AL109848	Streptomyces coelicolor cosmid I51.	Streptomyces coelicolor A3(2)	35,456	16-Aug-99
		GB_BA1.SCI51	40745	AL109848	Streptomyces coelicolor cosmid I51.	Streptomyces coelicolor A3(2)	37,576	16-Aug-99
		GB_EST31.A1704930	227	A1704930	U-R-AB1-ys-c-07-0-U1 s1 U-R-AB1 Rattus norvegicus cDNA clone U-R-AB1-ys-c-07-0-U1 3, mRNA sequence.	Rattus norvegicus	38,326	3-Jun-99
ra01290	1287	GB_HTG2.AC006892	299081	AC006892	Caenorhabditis elegans clone Y69A2, *** SEQUENCING IN PROGRESS *** , 10 unordered pieces.	Caenorhabditis elegans	33,727	26-Feb-99

00603034-00603077

**TABLE 4: ALIGNMENT RESULTS**

GB_HTG2:AC006892	299081	AC006892	Caenorhabditis elegans clone Y69A2, *** SEQUENCING IN PROGRESS ***, 10 unordered pieces.	Caenorhabditis elegans	33,727	26-Feb-99
GB_PR3:HS508115	131353	AL021707	Human DNA sequence from clone 508115 on chromosome 22q12-13 Contains gene for GTPBP1 (GTP binding protein 1), two novel genes KIAA0063 and KIAA0668, an mRNA, ESTs, STSs, GSSs, a CA repeat (D22S272) and CpG islands, complete sequence.	Homo sapiens	34,803	23-Nov-99
GB_BA1:MTCY16B7	43430	Z81331	Mycobacterium tuberculosis H37Rv complete genome; segment 123/162.	Mycobacterium tuberculosis	38,133	17-Jun-98
GB_BA1:MSGY414A	40121	AD000007	Mycobacterium tuberculosis sequence from clone y414a.	Mycobacterium tuberculosis	61,716	03-DEC-1996
GB_HTG4:AC010181	185244	AC010181	Homo sapiens chromosome 3 seeders clone RPC111-68L1, *** SEQUENCING IN PROGRESS ***, 26 unordered pieces.	Homo sapiens	34,807	21-OCT-1999
GB_BA1:MTCY16B7	43430	Z81331	Mycobacterium tuberculosis H37Rv complete genome; segment 123/162.	Mycobacterium tuberculosis	38,160	17-Jun-98
GB_BA1:MSGY414A	40121	AD000007	Mycobacterium tuberculosis sequence from clone y414a.	Mycobacterium tuberculosis	58,611	03-DEC-1996
GB_PL1:SCYJL013C	2289	Z49288	S. cerevisiae chromosome X reading frame ORF YJL013c.	Saccharomyces cerevisiae	36,180	11-Aug-97
GB_BA1:TTA5043	837	AJ225043	Thermus thermophilus partial nark gene.	Thermus thermophilus	55,245	18-Jun-98
GB_PL2:AC010675	84723	AC010675	Arabidopsis thaliana chromosome I BAC T17F3 genomic sequence, complete sequence.	Arabidopsis thaliana	37,058	11-Nov-99
GB_GSS9:AQ170862	518	AQ170862	HS_3165_B2_F03_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3165 Col=6 Row=L, genomic survey sequence.	Homo sapiens	38,610	17-OCT-1998
GB_BA1:MTCY10D7	39800	Z79700	Mycobacterium tuberculosis H37Rv complete genome; segment 44/162.	Mycobacterium tuberculosis	53,376	17-Jun-98
GB_BA1:MTCY39	38500	Z74025	Mycobacterium tuberculosis H37Rv complete genome; segment 89/162.	Mycobacterium tuberculosis	39,197	17-Jun-98
GB_BA1:MTCY251	38380	Z74410	Mycobacterium tuberculosis H37Rv complete genome; segment 5/162.	Mycobacterium tuberculosis	52,698	17-Jun-98
GB_JN1:DROPROS	6422	M81389	D.melanogaster Pros protein (prospero) mRNA, complete cds.	Drosophila melanogaster	37,229	26-Apr-93
GB_EST9:AA060074	688	AA060074	mj7307.r1 Soares mouse p3NMIF19.5 Mus musculus cDNA clone IMAGE:481765 5' similar to gb:X00246 Mouse mRNA with a Set 1 repetitive element for a class I (MOUSE); mRNA sequence.	Mus musculus	39,919	23-Sep-96
GB_EST16:AA560009	437	AA560009	v16a01.r1 Stralagene mouse Tcell 937311 Mus musculus cDNA clone IMAGE:972360 5' mRNA sequence.	Mus musculus	37,071	18-Aug-97
GB_BA1:CGLYSEG	2374	X96471	C. glutamicum lysE and lysG genes.	Corynebacterium glutamicum	38,462	24-Feb-97
GB_JN1:CELF28B3	36262	AF003136	Caenorhabditis elegans cosmid F28B3.	Caenorhabditis elegans	37,241	31-DEC-1997
GB_GSS13:AQ486324	573	AQ486324	RPC1-11-264E18, TJ RPC1-11 Homo sapiens genomic clone RPC1-11- 264E18, genomic survey sequence.	Homo sapiens	39,785	24-Apr-99

09503024-052700

TABLE 4: ALIGNMENT RESULTS

ra01411	888	GB_EST24:AU035428	756	AU035428	AU035428 Sugano mouse brain mncb	Mus musculus	37,112	08-OCT-1998
		GB_GSS12:AQ399225	621	AQ399225	0438, mRNA sequence.			
		GB_EST18:T42211	337	T42211	mgx0019C11f CUGI Rice Blast BAC Library Magnaporthe grisea genomic	Magnaporthe grisea	36,430	06-MAR-1999
					clone mgx0019C11f, genomic survey sequence.			
					5474 Lambda-PRL2 Arabidopsis thaliana cDNA clone 111C20T7, mRNA	Arabidopsis thaliana	42,433	7-Jan-98
					sequence.			
ra01454	367	GB_GSS5:AQ818876	486	AQ818876	HS_5297_B1_E12_SP6E RPC1-11 Human Male BAC Library Homo	Homo sapiens	36,585	26-Aug-99
					sapiens genomic clone Plate=873 Col=23 Row=L, genomic survey			
					sequence.			
		GB_EST19:AA778691	650	AA778691	af87n03.s1 Soares, Jests, NHT Homo sapiens cDNA clone 1049045 3'	Homo sapiens	32,344	5-Feb-98
					similar to contains L1.12 L1 repetitive element ;, mRNA sequence.			
		GB_GSS15:AQ599724	543	AQ599724	HS_5354_B1_B01_T7A RPC1-11 Human Male BAC Library Homo sapiens	Homo sapiens	39,773	10-Jun-99
					genomic clone Plate=930 Col=1 Row=D, genomic survey sequence.			
ra01455	585	GB_PL2:AF002169	5217	AF002169	Neurospora crassa coxI translation protein CYA5 (cya5) gene, complete	Neurospora crassa	39,161	24-MAR-1999
					cds.			
		GB_PL2:AF002169	5217	AF002169	Neurospora crassa coxI translation protein CYA5 (cya5) gene, complete	Neurospora crassa	37,565	24-MAR-1999
					cds.			
ra01625	324	GB_EST36:AV200593	300	AV200593	AV200593 Yiji Kohara unpublished cDNA Caenorhabditis elegans cDNA	Caenorhabditis elegans	43,284	26-Jul-99
					clone yk57710 3', mRNA sequence.			
		GB_PL1:S48358	414	S48358	tRNA Trp [Saccharomyces cerevisiae, Genomic, 414 nt].	Saccharomyces cerevisiae	37,143	08-MAY-1993
		GB_GSS8:AQ005656	390	AQ005656	CIT-HSP-2292G20 TR CIT-HSP Homo sapiens genomic clone 2292G20,	Homo sapiens	39,205	27-Jun-98
					genomic survey sequence.			
ra01756	1431	GB_HTG4:AC009886	163668	AC009886	Homo sapiens chromosome 15 clone 437_N_14 map 15, ***	Homo sapiens	35,865	19-OCT-1999
					SEQUENCING IN PROGRESS ***, 11 unordered pieces.			
		GB_HTG4:AC009886	163668	AC009886	Homo sapiens chromosome 15 clone 437_N_14 map 15, ***	Homo sapiens	35,865	19-OCT-1999
					SEQUENCING IN PROGRESS ***, 11 unordered pieces.			
		GB_EST6:N47950	424	N47950	yf84d12.s1 Soares, multiple, sclerosis_2NBHMSF Homo sapiens cDNA	Homo sapiens	38,261	14-Feb-96
					clone IMAGE:280247 3', mRNA sequence.			
ra01808	1172	GB_BA1:SEABCT	1976	X80735	S.erythraea (NCIMB 8594) erx gene for putative ABC transporter.	Saccharopolyspora erythraea	63,607	07-DEC-1995
		GB_BA1:MTV047	10866	AL022002	Mycobacterium tuberculosis H37Rv complete genome, segment 75/162.	Mycobacterium tuberculosis	40,563	17-Jun-98
ra01822	605	GB_BA1:ECOJW93	338534	U14003	Escherichia coli K-12 chromosomal region from 92.8 to 00.1 minutes.	Escherichia coli	35,112	17-Apr-96
					Homo sapiens chromosome 5 clone CIT-HSPC_397013, ***	Homo sapiens	35,940	3-Aug-99
					SEQUENCING IN PROGRESS ***, 36 unordered pieces.			
		GB_HTG3:AC008480	106822	AC008480	Homo sapiens chromosome 5 clone CIT-HSPC_397013, ***	Homo sapiens	35,940	3-Aug-99
					SEQUENCING IN PROGRESS ***, 36 unordered pieces.			
		GB_PL2:CNS01B8L	660	AL113917	Botrytis cinerea strain T4 cDNA library under conditions of nitrogen	Botryotinia fuckeliana	43,322	2-Sep-99
					deprivation.			
ra01900	1422	GB_BA2:AF056309	4346	AF056309	Streptomyces argillaceus membrane protein and mithramycin regulator	Streptomyces argillaceus	39,199	27-Jan-99
					MtmR (mtmR) genes, complete cds.			

00503724 1363377

**TABLE 4: ALIGNMENT RESULTS**

	GB_EST15:AU045582	273	AU045582	AU045582 Mouse sixteen-cell-embryo cDNA Mus musculus cDNA clone J0937H06.3', mRNA sequence.	Mus musculus	61,172	09-DEC-1998	
	GB_EST15:AA458642	217	AA458642	aa16b10.s1 Soares_NhhMPu_S1 Homo sapiens cDNA clone IMAGE:813403 3' similar to TR:G496330 G496330 (KBL MRNA.), mRNA sequence.	Homo sapiens	43,056	9-Jun-97	
rx01939	1854	GB_BA1:MTV025	121125	AL022121	Mycobacterium tuberculosis H37Rv complete genome; segment 155/162.	Mycobacterium tuberculosis	38,145	24-Jun-99
	GB_BA1:SC2A11	22789	AL031184	Streptomyces coelicolor cosmid 2A11.	Streptomyces coelicolor	45,783	5-Aug-98	
	GB_BA2:AE000431	11575	AE000431	Escherichia coli K-12 MG1655 section 321 of 400 of the complete genome.	Escherichia coli	38,384	12-Nov-98	
rx01972	717	GB_HTG2:AC007650	166670	AC007650	Drosophila melanogaster chromosome 3 clone BACR30G22 (D688) RPCI-98.30.G.22 map 87F-87F strain y; cn bw sp. *** SEQUENCING IN PROGRESS ***; 101 unordered pieces.	Drosophila melanogaster	37,712	2-Aug-99
	GB_HTG2:AC007650	166670	AC007650	Drosophila melanogaster chromosome 3 clone BACR30G22 (D688) RPCI-98.30.G.22 map 87F-87F strain y; cn bw sp. *** SEQUENCING IN PROGRESS ***; 101 unordered pieces.	Drosophila melanogaster	37,712	2-Aug-99	
	GB_HTG2:AC008204	138364	AC008204	Drosophila melanogaster chromosome 3 clone BACR04E17 (D762) RPCI-98.04.E.17 map 95E-95F strain y; cn bw sp. *** SEQUENCING IN PROGRESS***; 96 unordered pieces.	Drosophila melanogaster	36,827	2-Aug-99	
rx01995	1461	GB_HTG7:AC008065	172383	AC008065	Homo sapiens clone RP11-284E18, *** SEQUENCING IN PROGRESS ***; 4 unordered pieces.	Homo sapiens	37,213	09-DEC-1999
	GB_GSS5:AQ085794	426	AQ085794	HS_3192_A2_C04_MR CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3192 Col=8 Row=E, genomic survey sequence.	Homo sapiens	41,148	9-Aug-99	
	GB_GSS10:AQ173736	436	AQ173736	HS_3194_A1_C04_MR CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=3194 Col=7 Row=E, genomic survey sequence.	Homo sapiens	40,421	17-OCT-1998	
rx02034	1089	GB_PR4:AC002531	197900	AC002531	Homo sapiens chromosome Y, clone 486_O_8, complete sequence.	Homo sapiens	36,934	13-OCT-1999
	GB_PR2:HSB7L1C4	106710	AL078476	Homo sapiens chromosome 21 BAC B7L1C4, complete sequence.	Homo sapiens	34,454	9-Nov-99	
rx02035		GB_IN2:CELF26D11	36161	AF068716	Caenorhabditis elegans cosmid F26D11.	Caenorhabditis elegans	36,524	29-MAY-1998
rx02062	1293	GB_BA1:MTCI364	29540	Z93777	Mycobacterium tuberculosis H37Rv complete genome; segment 52/162.	Mycobacterium tuberculosis	38,606	17-Jun-98
	GB_EST34:AV153141	305	AV153141	AV153141 Mus musculus hippocampus C57BL/6J adult Mus musculus cDNA clone 2900053B17, mRNA sequence.	Mus musculus	37,705	7-Jul-99	
	GB_BA1:PHU88400	3855	U88400	Prochlorothrix hollandica hoxUVH operon, hydroxylase subunit Prochlorothrix (hoxU) gene, partial cds, and bidirectional hydroxylase small subunit (hoxY), unknown protein, and bidirectional hydroxylase large subunit (hoxH) genes, complete cds.	Prochlorothrix hollandica	38,712	05-MAY-1997	

[illegible]

1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
2	2	1	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
3	3	2	1	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
4	4	3	2	1	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
5	5	4	3	2	1	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
6	6	5	4	3	2	1	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
7	7	6	5	4	3	2	1	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
8	8	7	6	5	4	3	2	1	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
9	9	8	7	6	5	4	3	2	1	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
10	10	9	8	7	6	5	4	3	2	1	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
11	11	10	9	8	7	6	5	4	3	2	1	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
12	12	11	10	9	8	7	6	5	4	3	2	1	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
13	13	12	11	10	9	8	7	6	5	4	3	2	1	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
14	14	13	12	11	10	9	8	7	6	5	4	3	2	1	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
15	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
16	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
17	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
18	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63																																					

TABLE 4: ALIGNMENT RESULTS

ra02447	1118	GB_EST36:AI881490	551	AI881490	606069G06.y1 606 - Ear tissue cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence.	Zea mays	49,534	21-Jul-99
		GB_PL1:CKRNAHUP3	1605	X75440	C. kessleri HUP3 mRNA.	Chlorella kessleri	42,935	28-Jun-95
		GB_PL1:CKHUP1	2481	Y07520	Chlorella kessleri HUP1 mRNA for H(+)/hexose cotransporter.	Chlorella kessleri	43,379	12-Sep-93
ra02451	1647	GB_BA1:BRLBIOD	2272	D14083	Brevibacterium flavum genes for 7-8-diaminopelargonic acid aminotransferase and dethiobiotin synthetase, complete cds.	Corynebacterium glutamicum	40,496	3-Feb-99
		GB_PAT:E08643	285	E08643	Base sequence having the promoter function in Corynebacterium microorganisms.	Corynebacterium glutamicum	37,193	29-Sep-97
		GB_PL2:EF1245745	3194	AJ245745	Endonuclease fibuliger ura3 gene for orotidine-5-phosphate decarboxylase.	Saccharomyces copis fibuliger	38,889	24-Aug-99
ra02491	1377	GB_BA1:MTCY20G9	37218	Z77162	Mycobacterium tuberculosis H37Rv complete genome; segment 25/162.	Mycobacterium tuberculosis	55,745	17-Jun-98
		GB_BA1:CGL5UA	3492	X70959	C. glutamicum gene leuA for isopropylmalate synthase.	Corynebacterium glutamicum	38,253	10-Feb-99
		GB_PR3:AC004764	68048	AC004764	Homo sapiens chromosome 5, P1 clone 255g5 (LENL H61), complete sequence.	Homo sapiens	34,821	29-MAY-1998
ra02507	1524	GB_PR4:AC000134	203300	AC000134	Homo sapiens Chromosome 11q13 BAC Clone 137c7, complete sequence.	Homo sapiens	37,087	06-MAY-1999
		GB_PR2:HS227L5	85304	AL031585	Human DNA sequence from clone 227L5 on chromosome Xp11.22-11.3. Contains a Keratin, Type 1 Cytoskeletal 18 (KRT18, CYK18, K18, CK18) pseudogene and an STS, complete sequence.	Homo sapiens	38,718	23-Nov-99
		GB_PR4:AC000134	203300	AC000134	Homo sapiens Chromosome 11q13 BAC Clone 137c7, complete sequence.	Homo sapiens	35,955	06-MAY-1999
ra02515	879	GB_BA1:SCC22	22115	AL096839	Streptomyces coelicolor cosmid C22.	Streptomyces coelicolor	36,219	12-Jul-99
		GB_BA1:MTV007	32806	AL021184	Mycobacterium tuberculosis H37Rv complete genome; segment 64/162.	Mycobacterium tuberculosis	63,026	17-Jun-98
ra02562	843	GB_BA1:MLCL536	36224	Z99125	Mycobacterium leprae cosmid L536.	Mycobacterium leprae	36,468	04-DEC-1998
		GB_HTG7:AC011197	167967	AC011197	Homo sapiens clone RP11-322C8, *** SEQUENCING IN PROGRESS ***	Homo sapiens	36,675	08-DEC-1999
		GB_PAT:AR008238	6553	AR008238	Sequence 1 from patent US 5753442.	Unknown.	39,251	04-DEC-1998
		GB_GSS4:AQ712494	469	AQ712494	HS_2137_A1_A12_TTC CIT Approved Human Genomic Sperm Library D	Homo sapiens	35,664	13-Jul-99
					Homo sapiens genomic clone Plate=2137 Col=23 Row=A, genomic survey sequence.			
ra02595	1287	GB_BA1:MSGB983CS	36788	L78828	Mycobacterium leprae cosmid B983 DNA sequence.	Mycobacterium leprae	39,905	15-Jun-96
		GB_BA1:MLCB1883	43505	AL022486	Mycobacterium leprae cosmid B1883.	Mycobacterium leprae	52,909	27-Aug-99
		GB_GSS1:CNS0056G	994	AL057090	Drosophila melanogaster genome survey sequence T7 end of BAC # BACR11M23 of RPCI-98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.	Drosophila melanogaster	31,315	3-Jun-99
ra02597								
ra02605	618	GB_BA1:MXENC201	390	X92571	M. xenopi gene for 32 kDa protein (partial).	Mycobacterium xenopi	55,738	15-Jan-98

00503024-060300



TABLE 4: ALIGNMENT RESULTS

rx02614	852	GB_BA1:MXENO201	390	X92571	M.xenopi gene for 32 kDa protein (partial).	Mycobacterium xenopi	59,233	15-Jan-98
rx02614	852	GB_BA1:SCH35	45396	AL078610	Streptomyces coelicolor cosmid H35.	Streptomyces coelicolor	50,976	4-Jun-99
rx02614	852	GB_BA2:AF126201	12402	AF126201	Pseudomonas putida strain S-313 sulfate ester desulfurization gene locus, complete sequence.	Pseudomonas putida	46,763	12-OCT-1999
rx02616	834	GB_BA1:SC8B7	14634	AL031225	Streptomyces coelicolor cosmid 8B7.	Streptomyces coelicolor	38,026	7-Aug-98
rx02616	834	GB_BA1:SCD78	36224	AL034355	Streptomyces coelicolor cosmid D78.	Streptomyces coelicolor	43,705	26-Nov-98
rx02627	866	GB_EST28:AI509984	534	AI509984	mj18e06.y1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:476482.5, mRNA sequence.	Mus musculus	38,653	12-MAR-1999
rx02627	866	GB_EST8:AA050633	522	AA050633	mj18e06.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:476482.5, mRNA sequence.	Mus musculus	41,602	9-Sep-96
rx02627	866	GB_GSS6:AQ826046	427	AQ826046	HS_5311_B2_B01_SP6E RPCI-11 Human Male BAC Library/Homo sapiens genomic clone Plate=887 Col=2 Row=D, genomic survey sequence.	Homo sapiens	38,095	27-Aug-99
rx02628	528	GB_PR2:HS329F2	24753	AL031710	Human DNA sequence from clone LA16-329F2 on chromosome 16, complete sequence.	Homo sapiens	38,580	22-Nov-99
rx02628	528	GB_GSS10:AQ255771	621	AQ255771	nbxb0014E22r CUGI Rice BAC Library Oryza sativa genomic clone nbxb0014E22r, genomic survey sequence.	Oryza sativa	34,622	23-OCT-1998
rx02628	528	GB_BA1:RCAHIMA	5403	M84030	Rhodobacter capsulatus integration host factor (himA) gene, complete cds.	Rhodobacter capsulatus	37,452	26-Apr-93
rx02650	702	GB_GSS13:AQ476201	312	AQ476201	CITB1-E1-2592P3.IT CITB1-E1 Homo sapiens genomic clone 2592P3, genomic survey sequence.	Homo sapiens	43,182	23-Apr-99
rx02650	702	GB_EST38:AM054154	648	AM054154	614079C04.x1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence.	Zea mays	37,657	21-Sep-99
rx02650	702	GB_EST19:AA803900	441	AA803900	GM14564.5prime GM Drosophila melanogaster ovary pOT2 Drosophila melanogaster cDNA clone GM14564.5prime, mRNA sequence.	Drosophila melanogaster	40,394	25-Nov-98
rx02650	702	GB_EST19:AA803900	441	AA803900	GM14564.5prime GM Drosophila melanogaster ovary pOT2 Drosophila melanogaster cDNA clone GM14564.5prime, mRNA sequence.	Drosophila melanogaster	37,757	25-Nov-98
rx02660	762	GB_PR3:HS30801	166715	Z93403	Human genomic DNA sequence from clone 30801 on chromosome Xp11.3-Homo sapiens 11.4. Contains EST, CA repeat, STS, GSS, CpG island.	Homo sapiens	33,912	23-Nov-99
rx02661	342	GB_PR3:AC003669	159446	AC003669	Homo sapiens Xp22 BAC GS-594A7 (Genome Systems Human BAC library) contains Brnx gene, complete sequence.	Homo sapiens	35,734	24-MAR-1998
rx02661	342	GB_HTG3:AC010923	152021	AC010923	Drosophila melanogaster chromosome X clone BACR19K15 (D897) RPCI-98 19.K.15 map 15B-15E strain y; cn bw sp. *** SEQUENCING IN PROGRESS ***	Drosophila melanogaster	28,070	08-OCT-1999
rx02661	342	GB_HTG2:AC007802	118569	AC007802	Drosophila melanogaster chromosome 2 clone BACR0711 (D648) RPCI-98 07.11 map 58A1-58A2 strain y; cn bw sp. *** SEQUENCING IN PROGRESS ***	Drosophila melanogaster	43,373	2-Aug-99

00603034-062300

TABLE 4: ALIGNMENT RESULTS

rx02684	987	GB_PR2:CNS00006	181433	AL049775	Human chromosome 14 DNA sequence *** IN PROGRESS *** BAC R-497E19 of RPL-11 library from chromosome 14 of Homo sapiens (Human), complete sequence.	Homo sapiens	36,961	17-Jun-99
rx02684	987	GB_HTG3:AC009857	148241	AC009857	Homo sapiens clone 2_F_6, *** SEQUENCING IN PROGRESS *** , 9 unordered pieces.	Homo sapiens	35,380	3-Sep-99
rx02684	987	GB_HTG3:AC009857	148241	AC009857	Homo sapiens clone 2_F_6, *** SEQUENCING IN PROGRESS *** , 9 unordered pieces.	Homo sapiens	35,380	3-Sep-99
rx02684	987	GB_BA1:YEHEMSTUV	3901	X77867	Y. enterocolitica hemS, hemT, hemU and hemV genes.	Yersinia enterocolitica	48,253	11-OCT-1996
rx02684	987	GB_BA1:ECOUW76	225419	U00039	E. coli chromosomal region from 76.0 to 81.5 minutes.	Escherichia coli	39,177	7-Nov-96
rx02684	987	GB_HTG3:AC008616	112626	AC008616	Homo sapiens chromosome 19 clone CIT978SKB_144D21, *** SEQUENCING IN PROGRESS *** , 49 unordered pieces.	Homo sapiens	41,741	3-Sep-99
rx02750	939	GB_GSS15:AQ663436	430	AQ663436	HS_2160_B2_F10_TTC CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2160 Col=20 Row=L, genomic survey sequence.	Homo sapiens	42,020	23-Jun-99
rx02750	939	GB_GSS15:AQ663436	430	AQ663436	HS_2160_B2_F10_TTC CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2160 Col=20 Row=L, genomic survey sequence.	Homo sapiens	39,161	23-Jun-99
rx02795	1560	GB_HTG5:AC011134	192982	AC011134	Homo sapiens clone 1_A_23, *** SEQUENCING IN PROGRESS *** , 22 unordered pieces.	Homo sapiens	35,630	5-Nov-99
rx02795	1560	GB_HTG5:AC011134	192982	AC011134	Homo sapiens clone 1_A_23, *** SEQUENCING IN PROGRESS *** , 22 unordered pieces.	Homo sapiens	34,643	5-Nov-99
rx02808	281	GB_BA1:MTCY50	36030	Z77137	Mycobacterium tuberculosis H37Rv complete genome; segment 55/162.	Mycobacterium tuberculosis	39,934	17-Jun-98
rx02808	281	GB_PR4:AC004897	90731	AC004897	Homo sapiens PAC clone DJ0811N16 from 7q34-q36, complete sequence.	Homo sapiens	42,804	19-Aug-99
rx02808	281	GB_RO:AC002121	84056	AC002121	Genomic sequence from Mouse 11, complete sequence.	Mus musculus	39,130	10-Jul-97
rx02663	1518	GB_BA1:SC9F2	11908	AL035559	Streptomyces coelicolor cosmid 9F2.	Streptomyces coelicolor	45,964	25-Feb-99
rx02663	1518	GB_BA1:MTCY50	36030	Z77137	Mycobacterium tuberculosis H37Rv complete genome; segment 55/162.	Mycobacterium tuberculosis	38,998	17-Jun-98
rx02664	783	GB_BA1:D90721	16578	D90721	Escherichia coli genomic DNA, (18.6 - 19.0 min).	Escherichia coli	44,325	7-Feb-99
rx02664	783	GB_BA2:U32798	10423	U32798	Haemophilus influenzae Rd section 113 of 163 of the complete genome.	Haemophilus influenzae Rd	39,868	29-MAY-1998
rx02664	783	GB_BA1:HIU17295	9424	U17295	Haemophilus influenzae dppB, dppC, dppD, dppF, isf, artP, artI/J, artQ, and artM genes, complete cds, and opa gene, partial cds.	Haemophilus influenzae	49,298	4-Apr-96
rx02664	783	GB_BA2:U32792	11306	U32792	Haemophilus influenzae Rd section 107 of 163 of the complete genome.	Haemophilus influenzae Rd	39,764	29-MAY-1998

09603024-063300

**TABLE 4: ALIGNMENT RESULTS**

GB_PR4:AC005078	73231	AC005078	Homo sapiens BAC clone RG252K19 from 7p15.2-p21, complete sequence.	Homo sapiens	37,175	18-MAR-1999
rxs03220 725	GB_PL1:CKHUP2	2353	X66855	Chlorella kessleri	45,328	17-Feb-97
	GB_EST38:AW048153	383	AW048153	Mus musculus	41,758	18-Sep-99
			U1-M-BH1-a1q-h-05-0-U1.s1 NIH_BMAP_M_S2 Mus musculus cDNA clone			
			U1-M-BH1-a1q-h-05-0-U1.3, mRNA sequence.			
rxs03221 776	GB_PL1:CKHUP2	2353	X66855	Chlorella kessleri	38,106	17-Feb-97
	GB_BA1:BSUB0010	233780	Z99113	Bacillus subtilis	52,282	26-Nov-97
			C.kessleri HUP2 mRNA.			
			Bacillus subtilis complete genome (section 10 of 21): from 1781201 to 2014980.			
	GB_BA1:BSU66480	26114	U66480	Bacillus subtilis	52,282	22-Jan-97
			Bacillus subtilis SpoVK (spoVK), YnbA (ynbA), YnbB (ynbB), GlnR (glnR), glutamine synthetase (glnA), YnaA (ynaA), YnaB (ynab), YnaC (ynac), YnaD (ynad), YnaE (ynae), YnaF (ynaf), YnaG (ynag), YnaH (ynah), YnaI (ynai), YnaJ (ynaj), xylan beta-1,4-xylosidase (xynB), xylose repressor (xyIR), xylose isomerase (xyIA), xylose kinase (xyIB), YncB (yncB), YncC (yncC), YncD (yncD) and YncE (ynce) genes, complete cds.			
	GB_BA1:BSUB0010	233780	Z99113	Bacillus subtilis	36,983	26-Nov-97
			Bacillus subtilis complete genome (section 10 of 21): from 1781201 to 2014980.			

09603024-092900